The burden of proof: the current state of atrial fibrillation prevention and treatment trials by Zakeri, Rosita et al.
 
 
 
 
Zakeri, R. et al. (2017) The burden of proof: the current state of atrial 
fibrillation prevention and treatment trials. Heart Rhythm, 14(5), pp. 763-
782. (doi:10.1016/j.hrthm.2017.01.032) 
 
This is the author’s final accepted version. 
 
There may be differences between this version and the published version. 
You are advised to consult the publisher’s version if you wish to cite from 
it. 
 
 
 
 
http://eprints.gla.ac.uk/136817/ 
     
 
 
 
 
 
 
Deposited on: 09 March 2017 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
  The burden of proof: The current state of atrial fibrillation prevention and 
treatment trials 
 
Running title: AF prevention and treatment trials 
 
Rosita Zakeri, MBChB, PhD1; David R. Van Wagoner, PhD, FHRS2; Hugh Calkins, MD, 
FHRS3; Tom Wong, MD, FRCP1; Heather M. Ross, DNP, ANP-BC, FHRS4; E. Kevin 
Heist, MD, PhD, FHRS5; Timothy E. Meyer, PhD6; Peter R. Kowey, MD, FHRS7; Robert 
J. Mentz, MD8; John G. Cleland, MD1; Bertram Pitt, MD9, Faiez Zannad, MD, PhD10; 
Cecilia Linde, MD, PhD, MS11. 
 
1Royal Brompton & Harefield NHS Trust, London, UK; 2Cleveland Clinic, Cleveland, OH, 
USA; 3Johns Hopkins Hospital, Baltimore, MD, USA; 4Arizona State University, Phoenix, 
USA; 5Massachusetts General Hospital, Boston, MA, USA; 6Boston Scientific, USA; 
7Wynnewood, USA; 8Duke, NC, USA; 9University of Michigan, Ann Arbor, MI, USA; 
10Nancy, France; 11Karolinska Institute, Stockholm, Sweden. 
 
Word count: 15355  
 
Correspondence: 
Dr Rosita Zakeri, MBChB PhD 
Royal Brompton Hospital, Royal Brompton and Harefield NHS Trust 
Sydney Street, London, SW3 6NP 
Email: rosita.zakeri@doctors.org.uk 
Tel: +44-7752031231 
Fax: +44-2073518816 
 2 
Conflicts of interest: 
Dr Van Wagoner reports research grants from the National Institutes of Health and 
Amgen. Dr Heist is a consultant for Biotronik, Boston Scientific, Janssen, Medtronic, 
Pfizer, St Jude Medical; and receives research support from Boston Scientific and St. 
Jude Medical. Dr Kowey is a consultant for Sanofi, Gilead, Medtronic, BI, Daiichi, BMS, 
J&J. Dr Mentz receives research support from Medtronic. Professor Cleland is a 
consultant for Amgen, Bayer, BMS, CvRx, Novartis, Rietan, Sanofi, Servier, Stealth 
Biopharmaceuticals, Torrent, Vifor, Zoll; and receives research support from Amgen, 
CVRx, Novartis, Rietan, Stealth Pharmaceuticals, Torrent. Dr Pitt is a consultant for 
Bayer, Merck, Astra Zeneca , Boehringer Ingelheim ,Takeda,  Stealth peptides , 
cytopherex , Sarfez,   Relypsa*, scpharmaceuticals*, pharMain*, Kbp pharmaceuticals* , 
tricida, *DaVinci therapeutics* , Aurasense*. (*= stock options). He also has a patent 
pending for site-specific delivery of eplerenone to the myocardium. Dr Zannad is chair of 
the steering committee for Janssen. Dr Linde reports research grants, speaker 
honoraria, and consulting fees from Astra Zeneca, St. Jude Medical, Biotronik, 
Medtronic, Vifor, Cardio3 and Novartis. Other authors have reported that they have no 
relationships relevant to the contents of this manuscript to disclose. 
 
Funding: 
None  
 3 
Abstract 
Atrial fibrillation (AF) is an age-related arrhythmia of enormous socio-economic 
significance. In recent years, our understanding of the basic mechanisms that initiate 
and perpetuate AF has evolved rapidly, catheter ablation of AF has progressed from 
concept to reality, and recent studies suggest lifestyle modification may help prevent AF 
recurrence. Emerging developments in genetics, imaging, and informatics also present 
new opportunities for personalised care. However considerable challenges remain. 
These include a paucity of studies examining AF prevention, modest efficacy of existing 
antiarrhythmic therapies, diverse ablation technologies and practice, and limited 
evidence to guide management in high-risk patients with multiple comorbidities. Studies 
examining the long-term effects of AF catheter ablation on morbidity and mortality 
outcomes are not yet completed. In many ways, further progress in the field is heavily 
contingent on the feasibility, capacity and efficiency of clinical trials to incorporate the 
rapidly evolving knowledge base and to provide substantive evidence for novel AF 
therapeutic strategies.  This review outlines the current state of AF prevention and 
treatment trials including the foreseeable challenges, as discussed by a unique forum of 
clinical trialists, scientists, and regulatory representatives in a session endorsed by the 
Heart Rhythm Society at the 12th Global CardioVascular Clinical Trialists (CVCT) Forum 
in Washington, December 3-5, 2015. 
 
Key words: Atrial fibrillation; randomised controlled trial; prevention; ablation; 
personalised medicine.  
 4 
Introduction 
 Atrial fibrillation (AF) is a public health concern of global and epidemic 
proportions, inextricably linked to an aging population, expanding burden of predisposing 
factors, and enhanced arrhythmia surveillance1-3.  Symptoms associated with AF may be 
severe and disabling, and AF represents an independent risk factor for stroke, heart 
failure (HF), dementia, and death4, 5. Patients with AF are hospitalised twice as often as 
those without AF and the incremental costs attributable to AF-related care present 
important challenges for existing healthcare systems4-6. Accordingly, the treatment and 
prevention of AF has become a key priority for clinical and translational research efforts7-
9. 
 In recent years there have been significant advances in our understanding of the 
basic mechanisms underlying AF initiation and maintenance10, 11.  It has become clear 
that aging, genetics, environmental factors, cardiac and non-cardiac conditions further 
contribute to a favourable atrial substrate12. Moreover, surgical and catheter ablation 
techniques for AF have been at the forefront of rapid technological innovation4, 5, 13. 
Central to these endeavours, integration of basic science and observational findings into 
a defined therapeutic strategy and its uniform application and validation within a 
randomised controlled trial (RCT) has remained the benchmark for safety and efficacy 
required for any change in clinical practice14.  
 Currently, however, there are insufficient high quality and generalisable RCT 
data to support the needs of ‘real-world’ clinical practice15. Broadly speaking, prevailing 
challenges with respect to AF management include: i) limited RCT evidence relating to 
lifestyle and risk factor modification, prediction and prevention of AF, ii) diverse ablation 
practices, underrepresentation of long-term and patient reported outcomes within 
existing AF intervention trials, and iii) evolving demands for design and validation of 
personalised and mechanism-orientated AF therapies in order to improve patient 
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adherence and outcomes. A comprehensive discussion of these issues and the current 
state of AF prevention and treatment RCTs took place within a unique forum composed 
of clinical trialists, scientists, and regulatory representatives, at the 12th Global 
CardioVascular Clinical Trialists (CVCT) Forum in Washington, DC, December 3-5, 
2015, the details of which are outlined in this review. Note that AF-related stroke 
prevention and anticoagulation, whilst essential to AF management, are beyond the 
scope of this manuscript.  
 
AF prevention trials 
Primary and secondary AF prevention 
Epidemiological studies have described an array of potentially modifiable risk 
factors for AF including: hypertension, obesity, metabolic syndrome, diabetes mellitus, 
obstructive sleep apnoea, cigarette smoking, and excessive alcohol intake. Many of 
these are also risk factors for atherosclerotic cardiovascular disease, myocardial 
infarction and HF, which themselves predispose to AF. Recent consensus documents 
advocate targeting prevention efforts to individuals with the highest risk, typically those 
with multiple predisposing conditions8, 16. Putative risk scores have been developed with 
this in mind, though are not yet widely in use17.  
Unfortunately, the current framework for scientific investigation limits feasibility of 
dedicated AF primary prevention RCTs by the large population size and prolonged 
duration required to achieve an adequate number of recognised endpoints. A first 
presentation of symptomatic AF may occur years after recruitment and the expediency 
of prolonged ECG monitoring in asymptomatic individuals is low. Looking forwards, 
smartphone-based ECG applications, implantable and convenient wearable recorders 
with single-lead ECG recording capabilities are likely to become more pervasive in 
RCTs; emerging literature supports their utility and diagnostic performance in population-
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based settings18-20. Furthermore, detection of frequent atrial ectopy, may prove to be a 
precursor or surrogate marker of AF, allowing enrichment of study populations with 
individuals at sufficiently high risk21. Presently, however, further delineation of its natural 
history is required. 
Secondary prevention of AF (delaying recurrence of AF after an initial episode or 
delaying progression from paroxysmal to persistent AF) has received greater attention, 
albeit a clinical rather than pathological classification. Basic research in animal models 
and humans has demonstrated progressive atrial electrical and structural remodelling 
occurring in the setting of cardiometabolic risk factors, which are thought to be 
responsible for AF initiation and perpetuation of AFmaintenance11. Since this process 
develops insidiously, AF risk is realistically a continuum, and in most individuals will 
result from a combined effect of several interacting factors, often without definite 
threshold values. This may explain why isolated treatment of hypertension, although 
arguably one of the strongest contributors to AF burden22, has not been shown to reduce 
AF risk consistently and no target blood pressure has been identified. Hence, 
contemporary RCTs, as in clinical practice, have recognised the need to incorporate a 
strategy of comprehensive risk factor modification with individual AF prevention and 
treatment interventions. The fact that AF induces further electrical remodelling in animal 
models23 (‘AF begets AF’), further highlights the importance of early intervention.  
 
Non-pharmacological approaches to AF prevention  
Among candidate non-pharmacological interventions, inaugural studies of weight 
loss and exercise have shown efficacy for secondary, though not yet primary, AF 
prevention within a comprehensive risk factor modification programme (Table 1).  
 
Weight loss 
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Primary prevention RCT data regarding lifestyle intervention and weight loss in 
overweight and obese individuals with type II diabetes and no prior AF were available in 
the Look AHEAD trial24. Secondary analyses did not demonstrate a reduction in AF 
incidence over 9 years of follow up, though AF was not a pre-specified end-point and the 
overall weight loss achieved was modest24. Conversely, in overweight and obese 
patients with documented paroxysmal AF, randomised to a physician-instructed low-
calorie diet and exercise routine, Abed et al. reported a more significant reduction in BMI 
and improved blood pressure control at 15 months follow-up, associated with less 
frequent and shorter duration AF episodes (Holter monitoring) and lower self-reported 
symptom severity, compared with patients receiving standard lifestyle and weight loss 
advice25. Both groups received aggressive management of concomitant cardiometabolic 
risk factors. In ARREST-AF (Aggressive Risk Factor Reduction Study for Atrial 
Fibrillation and Implications for the Outcome of Ablation) overweight and obese patients 
undergoing first-time catheter ablation for either paroxysmal or persistent AF, who opted 
to undergo a focussed cardiometabolic risk factor management programme, showed 
consistently greater reductions in weight, systolic blood pressure, markers of AF burden, 
and freedom from AF recurrence (32.9% vs 9.7% in control subjects) at 42 months 
follow-up, compared with patients choosing standard post-ablation care26. Finally, a 
longitudinal cohort study of overweight and obese patients with paroxysmal or persistent 
AF participating in a physician-led weight management clinic (Long Term Effect of Goal 
Directed Weight Management on Atrial Fibrillation Cohort: A 5 year Follow-Up Study; 
LEGACY-AF), reported a dose-response relationship between weight loss and reduction 
in AF symptoms and arrhythmia burden (7-day Holter) at 5-year follow-up27. 
Taken together, the CVCT believes that these seminal findings from a dedicated 
single-centre team strongly support a strategy of purposeful weight loss to accompany 
risk factor modification for obese and overweight patients with existing AF. Replication of 
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these findings across multiple centres is now a priority for the clinical community and will 
require appropriate support from funding agencies. Notably, only one of the 
aforementioned studies was randomised25 and patients with significant valvular or 
ventricular dysfunction have so far been excluded.  
 
Exercise and cardiovascular fitness  
 Regular physical activity and aerobic exercise training delay development of 
atherosclerotic cardiovascular disease28. Exercise has been cautiously advocated in AF 
prevention and management, due to an increased risk of AF among individuals engaging 
in high-intensity and endurance training. However, it is worth highlighting that pro-
arrhythmic levels of exercise exceed those practised by the majority of patients with AF 
and recent data demonstrate an inverse relationship between physical activity and AF 
incidence in non-athlete cohorts29, 30, akin to a J-shaped phenomenon.  
Indeed, short-term exercise training has been shown to benefit secondary 
prevention of AF31, 32. The CardioFIT study (Impact of Cardiorespiratory Fitness on 
Arrhythmia Recurrence in Obese Individuals with Atrial Fibrillation), of overweight and 
obese patients with symptomatic paroxysmal or persistent AF, exhibited a dose-
response relationship between baseline cardiorespiratory fitness and long-term freedom 
from AF without antiarrhythmic drugs or ablation31. Cardiorespiratory fitness gain from a 
tailored programme of aerobic and resistance training further prolonged AF freedom, 
over and above the effect of weight loss31. Malmo et al. corroborated these findings in a 
referral cohort with paroxysmal or persistent AF undergoing first-time ablation, in a 
different centre, randomised to 12 weeks adjuvant high intensity aerobic interval training 
versus no exercise prescription32. Despite fewer cardiometabolic risk factors in this 
cohort, compared with prior prevention trials, exercise training yielded improvements in 
BMI, lipid profile and exercise capacity with attendant reduction in mean AF time 
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(implantable loop recording), and fewer and less severe self-reported AF symptoms, 
compared with the control group32.  
These data demonstrate that short-term gains in cardiorespiratory fitness are 
attainable, safe, and confer reductions in arrhythmia burden, with and without rhythm 
control strategies, in ambulatory patients with symptomatic AF. Whether these benefits 
can be sustained long-term now needs to be addressed. In the HF-ACTION trial, initial 
gains from supervised exercise training over 12-weeks were diluted by poor adherence 
when supervision ended, yielding modest overall improvement at final follow-up33. 
Furthermore, in LEGACY-AF, >5% annual fluctuation in weight partially offset the 
benefits of weight loss and exercise on arrhythmia-free survival at 5-years27. Thus, the 
CVCT Forum concluded that while public health-level arguments in favour of exercise 
and weight management programmes are strong, funding and resources for long-term 
physician-led face-to-face counselling and exercise clinics will be needed to realise their 
potential for AF prevention in clinical practice.  
 
Risk factor modification in patients with heart failure 
Patients with AF and HF present a unique challenge to the weight loss 
hypothesis. There are currently no published RCT data investigating the effect of weight 
loss in patients with AF and HF and it remains unclear whether severe atrial remodelling, 
as may occur in AF and HF, can be interrupted or reversed by weight loss, which is 
among its reported benefits. Furthermore, it is uncertain how weight loss interventions 
may impact the reported ‘obesity paradox’, in which overweight and mildly obese 
patients with HF appear to have better short-term outcomes compared with lean HF 
patients34. Interestingly, a similar paradox has been reported in a large trial cohort of 
patients with AF (without HF) on oral anticoagulant therapy35, despite compelling RCT 
data supporting weight loss for secondary AF prevention. Acknowledging that the nature 
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of this paradox remains controversial, future AF trials may benefit from more refined 
characterization of an obesity phenotype, beyond BMI alone. At present, however, 
empirical evidence does not support the practice of asking HF patients to lose weight 
and AF studies to date have not defined a target weight or weight range within which AF 
burden is minimised. Notably, cardiorespiratory fitness, itself associated with AF burden, 
reportedly alters the relationship between adiposity and prognosis in HF patients and 
attenuates the obesity paradox in younger patients with reduced ejection fraction36. 
Thus, the combined impact of exercise and weight optimisation in patients with AF and 
HF warrants prospective investigation. 
 
Pharmacological approaches to AF prevention 
 Upstream therapy refers to the use non-antiarrhythmic drugs to modify the atrial 
substrate or target specific mechanisms of AF37, 38. The concept is supported by 
compelling experimental evidence showing protective effects of renin-angiotensin-
aldosterone system (RAAS) inhibitors, statins, and polyunsaturated fatty acids, on atrial 
structural and electrical remodelling37, 38. Unfortunately, however, clinical performance of 
these agents in RCTs has been generally disappointing.  
RAAS inhibitors have been associated with reduced incidence of AF in patients 
with left ventricular systolic dysfunction or hypertrophy in retrospective analyses of RCTs 
with ≥3 years of follow-up38. The addition of a mineralocorticoid receptor antagonist 
(MRA), Eplerenone, to RAAS inhibition and beta-blockade was associated with a lower 
incidence of AF in patients with systolic heart failure (LVEF≤35%) and mild symptoms 
(NYHA class II) in the EMPHASIS trial39. No convincing benefit of RAAS inhibitors or 
MRAs has been observed in patients without underlying heart disease or for secondary 
AF prevention. In retrospective studies of patients undergoing cardiac surgery, statins 
appeared to protect against new-onset AF, though conflicting RCT data exist 40, 41. There 
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are insufficient clinical data to support the use of polyunsaturated fatty acids in primary 
or secondary prevention of AF37, 38. Only, short-term colchicine use has been associated 
with lower rates of post-operative AF42 and reduced early AF recurrence after catheter 
ablation43.  Concomitant reductions in inflammatory markers, C-reactive protein and 
Interleukin-6 support an anti-inflammatory mechanism. Colchicine use appears to be 
safe and generally well tolerated, although the optimal dose and duration need to be 
confirmed.  
As cardiac surgery and catheter ablation initiate inflammation, it is likely that 
colchicine’s anti-inflammatory action represents a good example of matching pathology 
with treatment. The failure of other agents to prevent AF in RCTs, despite convincing 
experimental data, may relate to inappropriately heterogeneous patient cohorts or a 
failure of experimental models to account for potentially neutralising effects of 
comorbidities accompanying AF. Upstream agents may be unable to reverse advanced 
atrial remodelling, and trials of generally ≤1 year duration may have been too short to 
demonstrate their effects. Future RCTs may consider combining agents or refining AF 
ascertainment methods to assess true impact on total AF burden. The Routine versus 
Aggressive upstream rhythm Control for prevention of Early AF in heart failure (RACE 3) 
RCT has taken this approach and will test the hypothesis that aggressive combination 
upstream therapy increases persistence of sinus rhythm in patients with early AF and 
mild-to-moderate early systolic or diastolic HF undergoing electrical cardioversion, when 
compared with conventional rhythm control alone (NCT00877643)44. 
 
AF treatment trials: Filling in the gaps 
Rate versus rhythm control 
 The major goals of AF therapy are to reduce cardiovascular symptoms and AF-
related morbidity and mortality. These aims should be pursued in parallel. Both rate and 
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rhythm control strategies have demonstrated improvements in quality of life and exercise 
capacity, however the first wave of large RCTs failed to show a mortality benefit with 
rhythm control45-49.  Reasons cited included a failure of rhythm control strategies to 
achieve and sustain sinus rhythm, a high rate of cross over between treatment arms, 
and harmful effects of antiarrhythmic drugs which may have offset the benefits of 
restoring sinus rhythm. Consequently, it remains uncertain as to whether one strategy is 
superior to the other with respect to major cardiovascular endpoints. A prevailing view is 
that AF at least contributes to its associated adverse outcomes, as well as representing 
a marker of cardiovascular disease, and thus a more efficacious and less toxic strategy 
of restoring and maintaining sinus rhythm is expected to improve prognosis. On-
treatment analysis of the AFFIRM trial suggested that sinus rhythm, where achieved, 
was associated with a reduction in mortality47; thus providing qualification for on-going 
efforts to optimise rhythm control. 
 
Non-pharmacological (invasive) approaches to AF treatment 
State-of-the-art non-pharmacological rhythm control therapy is based on 
radiofrequency endocardial catheter ablation, with pulmonary vein isolation (PVI) as the 
mainstay (Figure 1A). Prompted from a clinical observation50, translational research has 
corroborated the importance of pulmonary vein triggers for AF initiation, and several 
RCTs have demonstrated superiority of catheter ablation over antiarrhythmic drug 
therapy, with respect to freedom from arrhythmia recurrence, particularly in young 
patients with paroxysmal AF, and without major comorbidity51-55 (Table 2). Contemporary 
guidelines have endorsed catheter ablation for patients with symptomatic paroxysmal 
(class I) or persistent (class IIa) AF who are intolerant or resistant to one or more 
antiarrhythmic drugs5, 13. Importantly, however, this endorsement is not without caveats. 
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The Forum emphasized that available RCT and registry data show that PVI in its current 
form does not represent a cure for AF and several evidence gaps remain.  
 
Pulmonary vein isolation 
Only 50-66% of patients with paroxysmal AF achieve sustained sinus rhythm 
after a single PVI procedure and 70-80% after a second attempt56. Success rates are 
compromised further when follow-up is extended beyond 1 year56. These real world 
outcomes are inferior to the initial results reported by expert centres, prompting efforts to 
improve completeness of acute PVI (Table 3) and the discovery of PV reconnection as 
an important mechanism for AF recurrence57.  
Recent efficacy studies of novel irrigated-tip catheters have suggested an optimal 
contact force (CF) between the catheter tip and atrial tissue (20g with a force-time 
integral of 400g per ablation lesion58), which may improve transmural lesion formation 
and eliminate conduction gaps by improving lesion continuity. The first prospective 
multicentre RCT comparing CF-guided PVI against conventional PVI (TaciCath Contact 
Force Ablation Catheter Study For Atrial Fibrillation; TOCCASTAR59) met its primary 
non-inferiority safety and efficacy endpoints, and in secondary analyses reported that 
76% of CF-PVI patients were free from arrhythmia at 12 months off antiarrhythmic drugs 
compared with 58% undergoing non-CF ablation. Non-radiofrequency approaches are 
also being considered. Cryoablation utilises a balloon, positioned at the pulmonary vein 
ostia, which is cooled with liquid nitrous oxide. Iterative modifications have led to 
changes in freeze duration, homogeneity, balloon pressure and positioning, yielding 
greater efficacy and fewer serious complications (phrenic nerve paralysis, atrio-
oesophageal ulceration or fistula formation). The first prospective multicentre 
randomised trial of cryoablation versus conventional PVI recently met its non-inferiority 
safety and efficacy endpoints (Fire and Ice, Clinicaltrials.gov NCT01490814; Table 3)60. 
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Additionally, peri-procedural adenosine administration has been used to unmask 
‘dormant’ pulmonary veins ostensibly at risk of reconnecting, prompting further 
prophylactic lesion sets to be delivered during the index procedure. The multicentre 
ADVICE trial (Adenosine-guided pulmonary vein isolation for the treatment of 
paroxysmal atrial fibrillation: an international, multicentre, randomised superiority trial61) 
demonstrated improvement in 12-month arrhythmia-free survival with this approach 
compared with standard ablation practice, without an increase in periprocedural 
complications61. Still, the overall clinical impact of adenosine testing is likely to depend 
on the ablation technologies utilised, patient cohort, and resultant prevalence of dormant 
conduction. In the UNDER-ATP (UNmasking Dormant Electrical Reconduction by 
Adenosine TriPhosphate) trial, where the prevalence of dormant conduction after 
ablation with combined anatomical and electrophysiological guidance was 20-30% 
among patients with paroxysmal, persistent or longstanding persistent AF (versus 50% 
in the ADVICE trial), no significant reduction in the incidence of recurrent atrial 
arrhythmias was observed compared with conventional PVI62 (Table 3).  
It may be relevant that the positive aforementioned trials exclusively studied 
patients with paroxysmal AF. Even within this cohort, our understanding of the relevance 
of PV reconnection is derived from a biased subset of patients who have failed 
antiarrhythmic therapy and re-presented with symptomatic AF after a failed ablation. 
Purists may argue that PVI, at its conception, was never compared against a placebo 
control (i.e. sham-procedure), and thus the true effect size may have been 
overestimated. Indeed, RCTs in drug naïve patients comparing catheter ablation with 
antiarrhythmic drug therapy have either shown a lack of benefit or at best modest 
reduction in AF recurrence52, 54 (Table 2). Salient data from electrophysiology studies of 
patients without AF recurrence, have highlighted that pulmonary vein reconnection is 
also common in this setting57, 63, 64. Hence, while pulmonary vein sources are 
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undoubtedly associated with AF initiation and maintenance in many patients, the current 
trend of performing multiple procedures in order to attain complete PVI is largely without 
corroborating evidence for long-term or universal clinical benefit. 
 
Ablation of extra-pulmonary vein targets 
Ablation success rates for patients with persistent AF are lower than for 
paroxysmal AF, particularly in the setting of comorbidities65, ranging between 30-40% 
after a single or multiple procedures56, 66. Current guidelines recommend consideration of 
more extensive ablation in this cohort in order to address a higher number of non-
pulmonary vein triggers67. However RCT data for this approach has been inconsistent 
(Table 3). 
Creation of linear lesions to compartmentalize the left atrium has been 
incorporated into clinical practice, adopted from the surgical Cox-MAZE procedure68, and 
is thought to disrupt the critical mass of tissue needed to sustain AF (Figure 1B). 
Complex fractionated atrial electrograms (CFAEs) are electrograms of long duration, 
thought to highlight areas of slowed conduction and anchoring points for continuous re-
entry69, 70. Targeting CFAEs in patients with persistent AF has been associated with 
improved sinus rhythm maintenance in non-randomised studies and subgroup 
analyses71, 72 (Figure 1C). However, until recently, these empirical methods of substrate 
modification had little randomised or comparative data to support their use.  
In the largest multicentre RCT to date (Substrate and Trigger Ablation for 
Reduction of Atrial Fibrillation Trial Part II, STAR AF II73), three ablation strategies: PVI 
alone, PVI plus linear lesions (mitral isthmus and roof line), and PVI plus CFAE ablation, 
were compared in 589 patients undergoing first-time ablation for drug-refractory 
persistent AF. Contrary to expectations, no statistically significant difference in outcomes 
was observed after a first or repeat procedure (same strategy), with or without 
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antiarrhythmic drugs, at 18 months’ follow up. In fact, PVI alone tended to be superior at 
sinus rhythm maintenance, and was associated with shorter procedure and radiation 
times, though the trial was not adequately powered for this assessment. These 
compelling data highlight the importance of scientifically rigorous investigation to guide 
standard of care. Thus, in patients with persistent AF, there is currently no clear 
advantage to adjuvant CFAE ablations or empiric linear lesions not targeting 
arrhythmogenic substrate. 
That said, the discrepancy between index AF ablation success rates and long-
term pulmonary vein isolation has spurred interest in targeting other mechanisms of AF. 
Where present, ablation of patient-specific focal triggers may allow less overall tissue 
ablation, upholding the recommendations of STAR AF II. Proposed targets include: rapid 
drivers/dominant frequency, ganglion plexi ablation, and focal impulse or rotor 
modulation (FIRM).  
Dominant frequency ablation predicates that AF is driven by areas of high 
frequency activity not possessing the fractionation of CFAEs74. The RADAR-AF trial 
demonstrated that high frequency source ablation (HFSA) alone was not inferior to PVI 
for patients with paroxysmal AF at 12 months follow-up and displayed fewer 
complications, potentially due to less tissue ablation75. Conversely, for patients with 
persistent AF where a superiority endpoint was sought, HFSA failed to demonstrate 
incremental value when added to PVI75. The autonomic nervous system may modulate 
AF triggers and substrate76, 77. In patients with paroxysmal AF, ablation of peri-
pulmonary vein ganglion plexi (Figure 1D) was inferior to PVI alone, but when combined 
with PVI improved 2-year freedom from AF from 56% to 74%, without increasing the rate 
of iatrogenic atrial flutter78. An incremental effect of ganglion plexi ablation in patients 
with persistent AF has not yet been studied. A further body of research has proposed 
that spiral re-entry waves, or ‘rotors’, perpetuate AF. FIRM mapping software may be 
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used to identify and direct ablation of patient-specific rotors. The CONFIRM trial 
demonstrated that rotors were present in 97% of subjects with paroxysmal or persistent 
AF, and FIRM-guided cases of PVI exhibited higher rates of freedom from AF when 
compared with PVI alone79. The same investigators presented data corroborating FIRM-
guided ablation as a stand-alone procedure for patients with paroxysmal AF80, although 
this was not published and, controversially, others have been unable to replicate these 
findings81, 82.  
Summarising these studies, the Forum stresses that there is currently insufficient 
randomised evidence to change the ablative approach for persistent AF beyond isolated 
PVI, at least for an index procedure. Moving forward, the field would benefit from 
standardisation of the definitions used for extra-pulmonary vein targets and the approach 
to ablation; it may be argued that discrepancies in the prevalence, electrophysiological 
characteristics, and clinical outcomes between early studies largely result from 
methodological differences. Furthermore, it is not known whether successful ablation of 
AF, regardless of technique, will result in reduced mortality. This is under investigation in 
the Catheter Ablation versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation 
(CABANA; ClinicalTrials.gov NCT00911508) and Catheter Ablation versus Standard 
Conventional Treatment in Patients With LV Dysfunction and AF (CASTLE-AF; 
ClinicalTrials.gov NCT0064318883) trials. 
 
Additional considerations 
The rapid evolution of catheter designs and ablation techniques presents a 
challenge for evidence-based medicine and the premium placed on RCTs. Stringent 
protocols, high costs and cumbersome operational requirements have given rise to a 
number of short-duration trials, often with non-inferiority end points, where clinical 
decision making and patient choice may be better guided by demonstrating superiority of 
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one strategy over another and long-term outcomes. Equally disadvantageous is the 
prospect of a lengthy trial examining ablation strategies that vary markedly over time, 
where the primary outcome may be biased by earlier utilised and less efficacious 
techniques. There are some concerns this may apply to the CABANA trial 
(ClinicalTrials.gov NCT00911508). 
Operator proficiency and centre-related factors must also be considered. A 
worldwide survey in 2005 reported higher ablation success rates in high-volume 
compared with low-volume centres84. Single-85 and multicentre86 studies have also 
demonstrated an independent association between individual operator volume and 
procedure efficacy, complication rates and procedure times. Most importantly, the 
available evidence for AF catheter ablation has been derived from recognised regional, 
national and international centres of expertise. As a result, a consensus statement from 
the Heart Rhythm Society and European Heart Rhythm Association has been published 
specifying minimum institutional and operator criteria87. 
 
Patient reported outcome measures 
 Symptoms are a major reason that patients with AF seek medical attention and 
are the primary justification for ablation. In recognition of this, contemporary AF RCTs 
are increasingly utilising quality of life and AF-specific symptom questionnaires when 
comparing treatment strategies. However, these data continue to serve secondary 
endpoints or ancillary analyses. Probable impediments to the adoption of patient 
reported outcome measures (PROMs) as major endpoints in AF trials include the lack of 
an accepted gold standard assessment tool unique to AF, uncertainty regarding the 
fundamental mechanisms for symptoms or meaningful levels of change, and enormous 
heterogeneity in symptom profiles between and even within the same patients over time.  
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While there is no simple solution to these challenges, it is no longer acceptable to 
omit qualitative endpoints in an era of patient-centred medicine. This is particularly 
important where trade-offs may exist, for example between modestly efficacious 
antiarrhythmic drugs and potential associated adverse effects. Furthermore, although 
restoration of sinus rhythm remains the desired clinical goal, for some patients with 
symptomatic AF, a reduction in frequency or duration of AF episodes (AF burden) may 
be an acceptable outcome. Alternatively, improvement in functional capacity was 
demonstrated to be a feasible and clinically relevant AF intervention endpoint in the 
ARC-HF trial88. For other patients, a holistic approach to include detection and treatment 
of comorbidities may offer greater benefit. The impact of spironolactone on exercise 
capacity, health-related quality of life and left ventricular diastolic function in patients with 
AF and HF with preserved ejection fraction (HFpEF) is under investigation in the 
IMPRESS-AF trial (ClinicalTrials.gov NCT02673463). Wokhlu et al. observed that long-
term improvements in quality of life were unrelated to rhythm status in patients 
undergoing index AF ablation, though the exact reasons for this finding were unclear89.  
 Since the majority of tools used to assess quality of life, symptoms and functional 
status were not specifically developed for patients with AF, future systematic research is 
warranted to define the pathophysiological mechanisms underlying AF-related 
symptoms, their relationship to functional status, and their distinction, if any, from 
symptoms caused by other cardiac diseases such as heart failure and valvular disease.  
 
AF ablation in patients with heart failure 
 The vacillation between rate and rhythm control strategies for the management of 
AF extends to patients with HF and reduced ejection fraction (HFrEF). Persistent AF is 
more common in this group and adverse haemodynamic and neurohumoral factors 
present additional complexity. Nevertheless, among the few RCTs examining ablation as 
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second-line therapy in dedicated HFrEF cohorts, overall efficacy rates are similar to 
those for patients without HF, albeit repeat procedures are more often required (Table 
4). Improvements in quality of life, functional class and exercise tolerance have also 
been documented following AF ablation, when compared with atrioventricular node 
ablation90 and pharmacological rate control88, 91, though ablation was not superior to rate 
control in an early trial of digoxin therapy alone92. Notably, definitions of adequate 
ventricular rate control in HF remain arbitrary. Whether AF ablation can reduce the risk 
of death or major adverse cardiovascular events is currently being investigated in the 
CABANA, RAFT AF (A Randomised Ablation-based Atrial Fibrillation Rhythm Control 
Trial in Patients with Heart Failure and High Burden Atrial Fibrillation), and CASTLE AF 
(Catheter Ablation Versus Standard Conventional Treatment in Patients with Left 
Ventricular Dysfunction and Atrial Fibrillation) trials (Table 4). Encouraging results were 
recently obtained in the AATAC trial (Ablation Versus Amiodarone for Treatment of 
Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted 
Device) where AF ablation in HFrEF patients achieved greater freedom from AF, 
reduced mortality and fewer unplanned hospital admissions compared with amiodarone 
therapy93. 
 Outstanding areas in need of RCT level-evidence include the optimal AF 
management strategy for patients with HFpEF, and the role of catheter ablation as first-
line therapy for AF in patients with HF, although early rhythm control approaches are 
being considered in the CABANA and EAST AF trials (Table 4).  
 
Pharmacological approaches to AF treatment 
Ventricular rate control is recommended for all patients with AF, and a lenient 
strategy (resting heart rate <110bpm) is supported by the RACE II trial94. Beyond this, 
there is little RCT data to inform optimal heart rate targets or the choice of negatively 
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chronotropic agent with respect to morbidity, mortality and symptoms. Contemporary 
strategies are under evaluation in the pilot RATE AF study (Rate Control Therapy 
Evaluation in Permanent Atrial Fibrillation; NCT02391337). 
Antiarrhythmic drugs are recommended as first line therapy for patients with AF-
related symptoms after adequate rate control4, 5. Unfortunately, however, existing agents 
are of modest and unpredictable efficacy and confer significant risks of pro-arrhythmia 
and off-target adverse effects. Flecainide (Vaughan Williams class Ic) is frequently 
utilised in patients without structural heart disease, although amiodarone has the widest 
repertoire of antiarrhythmic actions and approximately twice the efficacy of class Ic and 
class III agents95. Even so, in the landmark Canadian Trial of Atrial Fibrillation (CTAF), 
35% of patients receiving amiodarone experienced AF recurrence at long-term follow up 
(mean 16 months) and 18% experienced adverse events requiring discontinuation of the 
drug95. The sheer size of the AF population and current restricted indications for catheter 
ablation indicate a large unmet need for more effective antiarrhythmic drugs to manage 
AF. 
Dronedarone, the first new anti-AF agent to appear in several years, was 
engineered to have structural similarities to amiodarone without the iodine moiety, thus 
eliminating thyroid toxicity. Dronedarone successfully reduced cardiovascular 
hospitalisation and death in patients with paroxysmal or persistent AF and one additional 
high-risk factor (ATHENA trial96). However, subsequent trials demonstrated increased 
mortality associated with its use in patients with structural heart disease and left 
ventricular dysfunction (PALLAS, ANDROMEDA97, 98). Dronedarone is now 
contraindicated in this setting.   
As with amiodarone, dronedarone has a non-specific mode of action that 
increases the risk of off-target effects. This has prompted the development of atrial-
specific agents with potentially superior efficacy and safety profiles. Although the 
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majority are still in pre-clinical studies, vernakalant, a novel Na+- and K+-channel blocker, 
has demonstrated efficacy and an acceptable safety profile for acute termination of new-
onset AF (<48h) in medium-sized placebo-controlled RCTs99-101 when compared with 
amiodarone (Active-controlled, superiority study of Vernakalant versus amiodarone in 
Recent Onset atrial fibrillation; AVRO trial102). Vernakalant has been approved by the 
European Medicines Agency for patients without structural heart disease, although there 
has been limited uptake; post-approval studies are currently underway. In the USA and 
Canada it remains an investigational drug. 
Overall, the sparse and slow progress in drug therapy for AF reflects existing 
barriers to pharmacological innovation. Even when limitations in AF experimental models 
and techniques have been navigated and initial validation in human studies attained, 
regulatory requirements for new drug development are strict. Understandable caution is 
exercised with regard to patient safety, however, it is widely appreciated that escalating 
operational complexity of drug RCTs and prohibitive costs have somewhat diminished 
interest from industry. Demands for large RCTs with mortality endpoints and the desire 
for profitable broad indications may also impede clinical translation of promising 
compounds. In view of these challenges, across the spectrum of cardiovascular disease, 
efforts are underway to improve clinical trial and regulatory enterprises103.  
 
Surgical and hybrid therapy for AF 
 The suboptimal efficacy of either pharmacological therapy or catheter ablation for 
AF has given rise to the concept of hybrid therapy. Antiarrhythmic drugs are frequently 
used in patients undergoing catheter ablation, though there is wide variation in clinical 
practice and no consensus or prospective randomised data confirming the optimal 
duration of adjuvant drug therapy. Open-chest surgical AF ablation is reserved for 
selected symptomatic patients who have failed catheter ablation and are typically 
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undergoing cardiac surgery for another indication4, 5. In this setting, epicardial ablation 
adds little additional operative risk. A novel minimally invasive approach, performed 
through video-assisted thoracoscopic surgery has also demonstrated superiority to 
catheter ablation in achieving one-year freedom from AF among patients with 
paroxysmal or persistent AF, with a dilated left atrium and hypertension, or previous 
failed catheter ablation104. However, periprocedural adverse event rates were notably 
higher in the surgical group, including pneumothorax, major bleeding and conversion to 
sternotomy104. The on-going multicentre CASA-AF trial will provide a contemporary 
appraisal of its safety and efficacy exclusively among patients with longstanding 
persistent AF (ClinicalTrials.gov NCT02755688).  
A hybrid approach, combining epicardial and endocardial ablation, has also been 
developed; providing freedom from AF rates approaching 90% at 1 year. Two small 
prospective studies reported superior 1- and 2-year outcomes compared with 
conventional percutaneous ablation in patients with persistent AF105, 106. Importantly, 
however, this strategy is still in its infancy and restricted to specialist centres with 
surgical expertise. Nevertheless, for patients without prohibitive surgical risk and 
symptomatic AF resistant to other therapies, it broadens future therapeutic options. 
Further data will be available from the on-going Hybrid versus Catheter Ablation in 
Persistent AF trial (HARTCAP-AF; ClinicalTrials.gov NCT02441738). 
 
Future directions: Towards personalised AF therapy 
 To some extent the clinical management of AF is already personalised4, 5. The 
decision to undergo cardioversion, ablation or to receive antiarrhythmic drug therapy is 
based on patient symptoms and preference. Additional consideration is given to 
comorbidities, duration of AF, left atrial size, drug efficacy, pharmacological interactions 
and adverse effects. Likewise, thromboembolism prophylaxis is prescribed according to 
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validated risk prediction scores based on clinical characteristics. However, despite 
nuanced clinical judgements, the complexity of AF remains a challenge and AF 
recurrence, progression to persistent AF, and response to treatment are largely 
unpredictable. This has prompted calls to improve our taxonomy of AF in order to 
facilitate a personalised or ‘precision medicine’ approach where therapy is tailored to an 
individual’s unique clinical, genetic and molecular determinants of disease.  
 
Substrate-guided therapy  
 The concept of electrical AF substrate characterisation is widely acknowledged 
and continues to inform the development of ablation techniques. However, recent trials, 
including STAR AF II, have demonstrated, that non-selective electrical substrate 
modification is not clearly associated with clinical benefit. To better tailor the 
interventional treatment of AF, more refined substrate characterisation alongside 
prospective delineation of AF triggers and drivers will be important. 
The 4th AFNET/EHRA consensus conference proposed a new clinical 
classification of AF incorporating distinct (monogenic, focally induced and post-operative 
AF) and complex subtypes (polygenic, valvular, and AF in the elderly)107.  Patients would 
be assigned to the most relevant group, ostensibly reflecting the dominant pathology of 
AF, while AF not fulfilling these definitions would be ‘unclassified’. Albeit, many patients 
will have overlapping mechanisms and ‘unclassified AF’ may be a common outcome. An 
alternative substrate-based approach has been proposed by an 
EHRA/HRS/APHRS/SOLAEC consensus group, describing the atrial cardiomyopathy 
associated with AF. EHRAS classes I to IV identify primarily cardiomyocyte-dependent, 
fibroblast-dependent (fibrotic), mixed-dependency, and primarily non-collagen atrial 
infiltration, respectively108. Although this classification is not intended to describe disease 
progression or severity, and may vary over time and atrial sites, the framework proposed 
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may enable the design of therapeutic strategies tailored to an individual’s 
histopathophysiology where atrial tissue is available for examination. In the majority of 
patients with AF, for whom atrial tissue is unlikely to be available or the risks of biopsy 
are not justified, advanced imaging techniques may provide an alternative means of 
substrate characterisation. 
 Left atrial enlargement, identified on echocardiography or cardiac magnetic 
resonance imaging (MRI), has traditionally been associated with failure of rhythm control 
in AF. More recently, left atrial fibrosis quantified by MRI has emerged as a potentially 
superseding structural marker of disease severity. Three-dimensional assessment of left 
atrial myocardial delayed enhancement (DE-MRI) as a marker of interstitial fibrosis has 
been correlated with areas of low voltage by electro-anatomical mapping109 and more 
frequent AF recurrence after index catheter ablation. In the DECAAF multicentre 
prospective observational study of patients with paroxysmal and persistent AF (n=272), 
the risk of recurrent AF increased from 15% for stage I fibrosis (<10% of the left atrial 
wall) to 69% for stage IV fibrosis (>30% left atrial wall fibrosis)110. This association 
persisted after covariate adjustment, including left atrial volume. Additional proof-of-
concept studies from specialist centres have demonstrated DE-MRI visualisation of 
catheter ablation lines111 and lesion gaps112. These data may assist patient selection for 
ablation, enabling priority to be given to patients with lower left atrial fibrotic burden, or in 
providing anatomical guidance for patients requiring a repeat procedure. This is currently 
being investigated in the DECAAFII trial (ClinicalTrials.gov NCT02529319). Importantly 
however, left atrial imaging is technically difficult and 17% of the initial DECAAF study 
cohort (n=57 subjects) were excluded due to poor quality DE-MRI images110. 
Furthermore, whether cardiac MRI has sufficient resolution to identity focal regions with 
incomplete scar remains uncertain. Additional development of cardiac MRI techniques, 
expertise, and correlation with electro-anatomical mapping will be an essential 
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prerequisite to its widespread application. Similarly, the use of circulating biomarkers of 
extracellular matrix remodelling and novel molecular imaging using radiotracers specific 
for cardiac fibrosis-related targets, while promising, are still early in development.   
 
Genotype-directed therapy 
In the last decade, positional cloning and candidate-gene approaches have 
identified rare forms of AF with Mendelian inheritance. Probands with AF, largely in the 
absence of structural heart disease, exhibit mutations within genes encoding cardiac ion 
channels113-115, gap junction proteins116, atrial natriuretic peptide (ANP)117 and 
nucleoporins (NUP155)118. For affected individuals, these mutations confer large effect 
sizes and might therefore permit gene-directed pharmacotherapy, although this 
approach has not yet been tested.  
From a population perspective, the goal is to elucidate common genetic variants 
identifying AF-susceptible individuals or AF subtypes who may benefit from preventive 
interventions or differentially respond to therapy. Thus far, genome wide association 
studies have identified 14 independent genetic loci with genome-wide significance119. 
While recognizing the small effect size of individual single nucleotide polymorphisms 
(SNPs), genetic risk may well be clinically meaningful in the presence of additional risk 
factors (‘two hit hypothesis’)120, 121. For example, an AF susceptibility allele at 
chromosome 4q25 (near the PITX2 gene) is present in approximately one-third of the 
general population and associated polymorphisms have been independently linked to AF 
recurrence following antiarrhythmic drug therapy122, cardioversion123, and catheter 
ablation124 in European cohorts, though not replicated in an Asian population125. Patients 
with a common β1 adrenergic receptor polymorphism (G389R) appear more likely to 
respond to a rate-control strategy and require lower doses of rate-lowering medication 
(beta-blockers or calcium channel antagonists) compared with non-G389R carriers126. 
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Other common SNPs have also been directly or inversely associated with greater 
prevalence of non-pulmonary vein triggers and enhanced left atrial scarring following 
catheter ablation127.  
Notably, a recent report from the AF-Gen consortium highlighted minimal 
incremental discriminatory value of polygenic AF risk scores when compared with 
recognised clinical risk factors for incident AF128. Thus, there are currently insufficient 
data to recommend routine genetic testing in patients with AF129, and caution must be 
attributed to case control studies and data mining of large registries where genotype-
phenotype associations may be skewed. RCT data are currently being sought after 
including a randomised genotype-directed sequential crossover study of flecainide and 
sotalol (ClinicalTrials.gov NCT02347111) and a pre-specified genotype association sub-
study of patients enrolled in the large CABANA trial (ClinicalTrials.gov NCT00911508).  
 
Pragmatic trial design for precision AF therapy 
 Our current classification of AF, based on duration of episodes, belies the diverse 
mechanisms underlying AF initiation and maintenance. Furthermore, classical RCTs 
informing AF management guidelines quantify an average treatment response for a 
uniformly applied therapeutic strategy, when compared with placebo or standard of care, 
typically within unselected populations. These approaches conceal individual phenotypic 
characteristics and treatment effects, including potentially informative data from outlying 
super- or non-responders, which could inform a precision medicine approach. Pre-
specified subgroup analyses are limited to high incidence subtypes that are frequently 
underpowered to demonstrate statistical benefit. Hence, while advances in genetics, 
informatics and imaging technologies will enable more refined classification and 
selection of patients with AF, concomitant changes in clinical trial design and accepted 
metrics of efficacy will likely also be needed to advance a precision medicine approach.  
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 Envisioned future management algorithms for AF may involve comprehensive 
genetic, biochemical and cardiac structural (imaging) profiling alongside routine clinical 
and electrocardiographic assessments (Figure 2). These data could be integrated into 
electronic health records and informatics platforms, with links to clinical registries and 
registry-networks, preferably equipped with intelligent real-time decision support tools, to 
assist classification of patients into relevant, small incidence, subtypes based on their 
dominant or relative contributions of different AF mechanisms. Extrapolating from 
principles of patient-centric trials in oncology130, all patients eligible for treatment may be 
presented with one of several rate or rhythm control treatment options within a single 
trial or network of trials (Figure 2). Where a reversible cause or suitable biomarker is 
available, therapies may be cause-specific and biomarker-guided. Unselected new 
therapeutic strategies may still be investigated for incremental benefit in single-arm, 
staged designs. Where no reversible cause is recognised, novel therapies may be 
compared with standard of care, in which patients are still monitored to provide 
opportunities for biomarker discovery and validation. A majority of AF patients screened 
would be assigned to a treatment option within a trial, thereby maximising therapeutic 
development while minimising the psychosocial, financial and time costs of screening 
failures. Large registries may also be used as a cost-effective and convenient platform 
for large-scale, simple clinical trials8, 131.  
With respect to data analyses, traditional interim analyses may be substituted by 
adaptive trial design features to allow modification of trial elements (e.g. sample size, 
randomisation ratio, number of treatment arms) based on accumulated results, with full 
control of type I error132. Greater use of repeated measures (e.g. serial imaging, 
assessment of PROMs) would allow detection of temporal changes in disease 
characteristics and treatment responses for individual patients. Consideration should be 
given to selecting endpoints most appropriate to the patients under study. Restoration 
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and maintenance of sinus rhythm may remain the desired outcome for symptomatic 
patients with isolated paroxysmal AF, whereas in patients with AF and heart failure, 
delineating global determinants of impaired functional capacity may be of greater clinical 
value. Increasingly, remote or implantable monitoring technologies can be utilised to 
quantify AF burden as well as symptomatically ‘silent’ AF recurrences following 
intervention. The association between device-detected AF and adverse outcomes, 
including stroke risk, is an active area of investigation and the field awaits the definition 
of an acceptable threshold of AF burden, if any133. Finally, recent literature has 
highlighted the shifting epidemiology of AF, with heart failure now representing the most 
common incident non-fatal event after AF diagnosis134. Moving forward, it is incumbent 
on AF registries and long-term intervention trials to include incident HF as a legitimate 
endpoint alongside mortality and stroke rates.  
Ultimately, successful and integrated development of AF precision medicine 
strategies will require wide collaboration between investigators, industry and regulatory 
groups to ensure standardisation of practice, broad access to therapeutics in 
development, and adequate scientific rigour to support clinical translation.  
 
Conclusion 
 Several decades of concerted research has increased our understanding of the 
mechanisms underlying AF and given rise to novel therapeutic strategies. Systematic 
validation of these in RCTs has reliably informed evidence-based practice and produced 
broad improvements in health outcomes. However, significant evidence gaps remain in 
our understanding of the AF substrate and traditional RCTs designed for the ‘average’ 
patient incompletely address the complexity of the AF population. In realising the value 
of individual patient characteristics and treatment responses, the concept of precision 
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medicine offers exciting opportunities to accelerate clinical translation of targeted 
interventions designed to treat and prevent AF.  
  
 31 
References 
1. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, 
Seward JB and Tsang TS. Secular trends in incidence of atrial fibrillation in Olmsted 
County, Minnesota, 1980 to 2000, and implications on the projections for future 
prevalence. Circulation. 2006;114:119-25. 
2. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial 
fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129:837-47. 
3. Schnabel RB, Yin X, Gona P, et al. 50 year trends in atrial fibrillation prevalence, 
incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. 
Lancet. 2015;386:154-62. 
4. Camm AJ, Kirchhof P, Lip GY, et al. European Heart Rhythm Association and 
European Association for Cardio-Thoracic Surgery. Guidelines for the management of 
atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European 
Society of Cardiology (ESC). Eur Heart J. 2010;31:2369-429. 
5. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the 
management of patients with atrial fibrillation: a report of the American College of 
Cardiology/American Heart Association Task Force on Practice Guidelines and the 
Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1-76. 
6. Kim MH, Johnston SS, Chu BC, Dalal MR and Schulman KL. Estimation of total 
incremental health care costs in patients with atrial fibrillation in the United States. Circ 
Cardiovasc Qual Outcomes. 2011;4:313-20. 
7. Committee on Comparative Effectiveness Research Prioritization IoM. Initial 
National Priorities for Comparative Effectiveness Research. 2009. 
8. Van Wagoner DR, Piccini JP, Albert CM, et al. Progress toward the prevention 
and treatment of atrial fibrillation: A summary of the Heart Rhythm Society Research 
Forum on the Treatment and Prevention of Atrial Fibrillation, Washington, DC, 
December 9-10, 2013. Heart Rhythm. 2015;12:e5-e29. 
9. Kirchhof P, Breithardt G, Bax J, et al. A roadmap to improve the quality of atrial 
fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European 
Heart Rhythm Association consensus conference. Europace. 2016;18:37-50. 
10. Nattel S, Burstein B and Dobrev D. Atrial remodeling and atrial fibrillation: 
mechanisms and implications. Circ Arrhythm Electrophysiol. 2008;1:62-73. 
11. Schotten U, Verheule S, Kirchhof P and Goette A. Pathophysiological 
mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev. 2011;91:265-325. 
12. Goette A, Kalman JM, Aguinaga L, et al. EHRA/HRS/APHRS/SOLAECE expert 
consensus on atrial cardiomyopathies: Definition, characterization, and clinical 
implication. Heart Rhythm. 2016. 
 32 
13. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the 
management of atrial fibrillation developed in collaboration with EACTS: The Task Force 
for the management of atrial fibrillation of the European Society of Cardiology 
(ESC)Developed with the special contribution of the European Heart Rhythm 
Association (EHRA) of the ESCEndorsed by the European Stroke Organisation (ESO). 
Eur Heart J. 2016. 
14. Collins R and MacMahon S. Reliable assessment of the effects of treatment on 
mortality and major morbidity, I: clinical trials. Lancet. 2001;357:373-80. 
15. Tricoci P, Allen JM, Kramer JM, Califf RM and Smith SC, Jr. Scientific evidence 
underlying the ACC/AHA clinical practice guidelines. JAMA. 2009;301:831-41. 
16. Benjamin EJ, Chen PS, Bild DE, et al. Prevention of atrial fibrillation: report from 
a national heart, lung, and blood institute workshop. Circulation. 2009;119:606-18. 
17. Alonso A, Krijthe BP, Aspelund T, et al. Simple risk model predicts incidence of 
atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF 
consortium. J Am Heart Assoc. 2013;2:e000102. 
18. Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, 
Rymer MM, Thijs V, Rogers T, Beckers F, Lindborg K, Brachmann J and Investigators 
CA. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014;370:2478-
86. 
19. Chan PH, Wong CK, Poh YC, Pun L, Leung WW, Wong YF, Wong MM, Poh MZ, 
Chu DW and Siu CW. Diagnostic Performance of a Smartphone-Based 
Photoplethysmographic Application for Atrial Fibrillation Screening in a Primary Care 
Setting. J Am Heart Assoc. 2016;5. 
20. Steinhubl SR, Mehta RR, Ebner GS, et al. Rationale and design of a home-
based trial using wearable sensors to detect asymptomatic atrial fibrillation in a targeted 
population: The mHealth Screening To Prevent Strokes (mSToPS) trial. Am Heart J. 
2016;175:77-85. 
21. Dewland TA, Vittinghoff E, Mandyam MC, Heckbert SR, Siscovick DS, Stein PK, 
Psaty BM, Sotoodehnia N, Gottdiener JS and Marcus GM. Atrial ectopy as a predictor of 
incident atrial fibrillation: a cohort study. Ann Intern Med. 2013;159:721-8. 
22. Huxley RR, Lopez FL, Folsom AR, Agarwal SK, Loehr LR, Soliman EZ, 
Maclehose R, Konety S and Alonso A. Absolute and attributable risks of atrial fibrillation 
in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities 
(ARIC) study. Circulation. 2011;123:1501-8. 
23. Wijffels MC, Kirchhof CJ, Dorland R, Power J and Allessie MA. Electrical 
remodeling due to atrial fibrillation in chronically instrumented conscious goats: roles of 
neurohumoral changes, ischemia, atrial stretch, and high rate of electrical activation. 
Circulation. 1997;96:3710-20. 
24. Alonso A, Bahnson JL, Gaussoin SA, Bertoni AG, Johnson KC, Lewis CE, Vetter 
M, Mantzoros CS, Jeffery RW, Soliman EZ and Look ARG. Effect of an intensive lifestyle 
 33 
intervention on atrial fibrillation risk in individuals with type 2 diabetes: the Look AHEAD 
randomized trial. Am Heart J. 2015;170:770-777 e5. 
25. Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and 
cardiometabolic risk factor management on symptom burden and severity in patients 
with atrial fibrillation: a randomized clinical trial. JAMA. 2013;310:2050-60. 
26. Pathak RK, Middeldorp ME, Lau DH, et al. Aggressive risk factor reduction study 
for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort 
study. J Am Coll Cardiol. 2014;64:2222-31. 
27. Pathak RK, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Wong CX, 
Twomey D, Elliott AD, Kalman JM, Abhayaratna WP, Lau DH and Sanders P. Long-
Term Effect of Goal-Directed Weight Management in an Atrial Fibrillation Cohort: A 
Long-Term Follow-Up Study (LEGACY). J Am Coll Cardiol. 2015;65:2159-69. 
28. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular 
disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the 
European Society of Cardiology and Other Societies on Cardiovascular Disease 
Prevention in Clinical Practice (constituted by representatives of nine societies and by 
invited experts). Eur Heart J. 2012;33:1635-701. 
29. Mozaffarian D, Furberg CD, Psaty BM and Siscovick D. Physical activity and 
incidence of atrial fibrillation in older adults: the cardiovascular health study. Circulation. 
2008;118:800-7. 
30. Drca N, Wolk A, Jensen-Urstad M and Larsson SC. Physical activity is 
associated with a reduced risk of atrial fibrillation in middle-aged and elderly women. 
Heart. 2015;101:1627-30. 
31. Pathak RK, Elliott A, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, 
Hendriks JM, Twomey D, Kalman JM, Abhayaratna WP, Lau DH and Sanders P. Impact 
of CARDIOrespiratory FITness on Arrhythmia Recurrence in Obese Individuals With 
Atrial Fibrillation: The CARDIO-FIT Study. J Am Coll Cardiol. 2015;66:985-96. 
32. Malmo V, Nes BM, Amundsen BH, Tjonna AE, Stoylen A, Rossvoll O, Wisloff U 
and Loennechen JP. Aerobic Interval Training Reduces the Burden of Atrial Fibrillation in 
the Short Term: A Randomized Trial. Circulation. 2016;133:466-73. 
33. O'Connor CM, Whellan DJ, Lee KL, et al. Efficacy and safety of exercise training 
in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA. 
2009;301:1439-50. 
34. Clark AL, Fonarow GC and Horwich TB. Obesity and the obesity paradox in heart 
failure. Prog Cardiovasc Dis. 2014;56:409-14. 
35. Sandhu RK, Ezekowitz J, Andersson U, Alexander JH, Granger CB, Halvorsen 
S, Hanna M, Hijazi Z, Jansky P, Lopes RD and Wallentin L. The 'obesity paradox' in 
atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke 
and Other Thromboembolic Events in Atrial Fibrillation) trial. Eur Heart J. 2016. 
 34 
36. Lavie CJ, Cahalin LP, Chase P, Myers J, Bensimhon D, Peberdy MA, Ashley E, 
West E, Forman DE, Guazzi M and Arena R. Impact of cardiorespiratory fitness on the 
obesity paradox in patients with heart failure. Mayo Clin Proc. 2013;88:251-8. 
37. Savelieva I, Kakouros N, Kourliouros A and Camm AJ. Upstream therapies for 
management of atrial fibrillation: review of clinical evidence and implications for 
European Society of Cardiology guidelines. Part I: primary prevention. Europace. 
2011;13:308-28. 
38. Savelieva I, Kakouros N, Kourliouros A and Camm AJ. Upstream therapies for 
management of atrial fibrillation: review of clinical evidence and implications for 
European Society of Cardiology guidelines. Part II: secondary prevention. Europace. 
2011;13:610-25. 
39. Swedberg K, Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Shi H, 
Vincent J, Pitt B and Investigators Emphasis-HF. Eplerenone and atrial fibrillation in mild 
systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients 
Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol. 
2012;59:1598-603. 
40. Chen WT, Krishnan GM, Sood N, Kluger J and Coleman CI. Effect of statins on 
atrial fibrillation after cardiac surgery: a duration- and dose-response meta-analysis. J 
Thorac Cardiovasc Surg. 2010;140:364-72. 
41. Zheng Z, Jayaram R, Jiang L, Emberson J, Zhao Y, Li Q, Du J, Guarguagli S, Hill 
M, Chen Z, Collins R and Casadei B. Perioperative Rosuvastatin in Cardiac Surgery. N 
Engl J Med. 2016;374:1744-53. 
42. Imazio M, Brucato A, Ferrazzi P, et al. Colchicine reduces postoperative atrial 
fibrillation: results of the Colchicine for the Prevention of the Postpericardiotomy 
Syndrome (COPPS) atrial fibrillation substudy. Circulation. 2011;124:2290-5. 
43. Deftereos S, Giannopoulos G, Kossyvakis C, et al. Colchicine for prevention of 
early atrial fibrillation recurrence after pulmonary vein isolation: a randomized controlled 
study. J Am Coll Cardiol. 2012;60:1790-6. 
44. Alings M, Smit MD, Moes ML, et al. Routine versus aggressive upstream rhythm 
control for prevention of early atrial fibrillation in heart failure: background, aims and 
design of the RACE 3 study. Neth Heart J. 2013;21:354-63. 
45. Carlsson J, Miketic S, Windeler J, Cuneo A, Haun S, Micus S, Walter S, Tebbe U 
and STAF Investigators. Randomized trial of rate-control versus rhythm-control in 
persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. 
J Am Coll Cardiol. 2003;41:1690-6. 
46. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, 
Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD and Atrial Fibrillation Follow-
up Investigation of Rhythm Management Investigators. A comparison of rate control and 
rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825-33. 
 35 
47. Corley SD, Epstein AE, DiMarco JP, et al. Relationships between sinus rhythm, 
treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm 
Management (AFFIRM) Study. Circulation. 2004;109:1509-13. 
48. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, Said 
SA, Darmanata JI, Timmermans AJ, Tijssen JG, Crijns HJ and Rate Control versus 
Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of 
rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N 
Engl J Med. 2002;347:1834-40. 
49. Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial 
fibrillation and heart failure. N Engl J Med. 2008;358:2667-77. 
50. Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G, Garrigue 
S, Le Mouroux A, Le Metayer P and Clementy J. Spontaneous initiation of atrial 
fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 
1998;339:659-66. 
51. Jais P, Cauchemez B, Macle L, et al. Catheter ablation versus antiarrhythmic 
drugs for atrial fibrillation: the A4 study. Circulation. 2008;118:2498-505. 
52. Morillo CA, Verma A, Connolly SJ, Kuck KH, Nair GM, Champagne J, Sterns LD, 
Beresh H, Healey JS, Natale A and RAAFT-2 Investigators. Radiofrequency ablation vs 
antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a 
randomized trial. JAMA. 2014;311:692-700. 
53. Hakalahti A, Biancari F, Nielsen JC and Raatikainen MJ. Radiofrequency 
ablation vs. antiarrhythmic drug therapy as first line treatment of symptomatic atrial 
fibrillation: systematic review and meta-analysis. Europace. 2015;17:370-8. 
54. Cosedis Nielsen J, Johannessen A, Raatikainen P, Hindricks G, Walfridsson H, 
Kongstad O, Pehrson S, Englund A, Hartikainen J, Mortensen LS and Hansen PS. 
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. N Engl J Med. 
2012;367:1587-95. 
55. Wilber DJ, Pappone C, Neuzil P, et al. Comparison of antiarrhythmic drug 
therapy and radiofrequency catheter ablation in patients with paroxysmal atrial 
fibrillation: a randomized controlled trial. JAMA. 2010;303:333-40. 
56. Ganesan AN, Shipp NJ, Brooks AG, Kuklik P, Lau DH, Lim HS, Sullivan T, 
Roberts-Thomson KC and Sanders P. Long-term outcomes of catheter ablation of atrial 
fibrillation: a systematic review and meta-analysis. J Am Heart Assoc. 2013;2:e004549. 
57. Ouyang F, Antz M, Ernst S, et al. Recovered pulmonary vein conduction as a 
dominant factor for recurrent atrial tachyarrhythmias after complete circular isolation of 
the pulmonary veins: lessons from double Lasso technique. Circulation. 2005;111:127-
35. 
58. Neuzil P, Reddy VY, Kautzner J, Petru J, Wichterle D, Shah D, Lambert H, 
Yulzari A, Wissner E and Kuck KH. Electrical reconnection after pulmonary vein isolation 
 36 
is contingent on contact force during initial treatment: results from the EFFICAS I study. 
Circ Arrhythm Electrophysiol. 2013;6:327-33. 
59. Reddy VY, Dukkipati SR, Neuzil P, et al. Randomized, Controlled Trial of the 
Safety and Effectiveness of a Contact Force-Sensing Irrigated Catheter for Ablation of 
Paroxysmal Atrial Fibrillation: Results of the TactiCath Contact Force Ablation Catheter 
Study for Atrial Fibrillation (TOCCASTAR) Study. Circulation. 2015;132:907-15. 
60. Furnkranz A, Brugada J, Albenque JP, Tondo C, Bestehorn K, Wegscheider K, 
Ouyang F and Kuck KH. Rationale and Design of FIRE AND ICE: A multicenter 
randomized trial comparing efficacy and safety of pulmonary vein isolation using a 
cryoballoon versus radiofrequency ablation with 3D-reconstruction. J Cardiovasc 
Electrophysiol. 2014;25:1314-20. 
61. Macle L, Khairy P, Weerasooriya R, et al. Adenosine-guided pulmonary vein 
isolation for the treatment of paroxysmal atrial fibrillation: an international, multicentre, 
randomised superiority trial. Lancet. 2015;386:672-9. 
62. Kobori A, Shizuta S, Inoue K, et al. Adenosine triphosphate-guided pulmonary 
vein isolation for atrial fibrillation: the UNmasking Dormant Electrical Reconduction by 
Adenosine TriPhosphate (UNDER-ATP) trial. Eur Heart J. 2015;36:3276-87. 
63. Jiang RH, Po SS, Tung R, Liu Q, Sheng X, Zhang ZW, Sun YX, Yu L, Zhang P, 
Fu GS and Jiang CY. Incidence of pulmonary vein conduction recovery in patients 
without clinical recurrence after ablation of paroxysmal atrial fibrillation: mechanistic 
implications. Heart Rhythm. 2014;11:969-76. 
64. Cappato R, Negroni S, Pecora D, Bentivegna S, Lupo PP, Carolei A, Esposito C, 
Furlanello F and De Ambroggi L. Prospective assessment of late conduction recurrence 
across radiofrequency lesions producing electrical disconnection at the pulmonary vein 
ostium in patients with atrial fibrillation. Circulation. 2003;108:1599-604. 
65. Jacobs V, May HT, Bair TL, Crandall BG, Cutler M, Day JD, Weiss JP, Osborn 
JS, Muhlestein JB, Anderson JL, Mallender C and Bunch TJ. The impact of risk score 
(CHADS2 versus CHA2DS2-VASc) on long-term outcomes after atrial fibrillation 
ablation. Heart Rhythm. 2015;12:681-6. 
66. Brooks AG, Stiles MK, Laborderie J, Lau DH, Kuklik P, Shipp NJ, Hsu LF and 
Sanders P. Outcomes of long-standing persistent atrial fibrillation ablation: a systematic 
review. Heart Rhythm. 2010;7:835-46. 
67. Kurotobi T, Iwakura K, Inoue K, Kimura R, Okamura A, Koyama Y, Tosyoshima 
Y, Ito N and Fujii K. Multiple arrhythmogenic foci associated with the development of 
perpetuation of atrial fibrillation. Circ Arrhythm Electrophysiol. 2010;3:39-45. 
68. Cox JL, Schuessler RB, D'Agostino HJ, Jr., Stone CM, Chang BC, Cain ME, Corr 
PB and Boineau JP. The surgical treatment of atrial fibrillation. III. Development of a 
definitive surgical procedure. J Thorac Cardiovasc Surg. 1991;101:569-83. 
 37 
69. Konings KT, Smeets JL, Penn OC, Wellens HJ and Allessie MA. Configuration of 
unipolar atrial electrograms during electrically induced atrial fibrillation in humans. 
Circulation. 1997;95:1231-41. 
70. Nademanee K, McKenzie J, Kosar E, Schwab M, Sunsaneewitayakul B, 
Vasavakul T, Khunnawat C and Ngarmukos T. A new approach for catheter ablation of 
atrial fibrillation: mapping of the electrophysiologic substrate. J Am Coll Cardiol. 
2004;43:2044-53. 
71. Li WJ, Bai YY, Zhang HY, Tang RB, Miao CL, Sang CH, Yin XD, Dong JZ and 
Ma CS. Additional ablation of complex fractionated atrial electrograms after pulmonary 
vein isolation in patients with atrial fibrillation: a meta-analysis. Circ Arrhythm 
Electrophysiol. 2011;4:143-8. 
72. Verma A, Novak P, Macle L, Whaley B, Beardsall M, Wulffhart Z and Khaykin Y. 
A prospective, multicenter evaluation of ablating complex fractionated electrograms 
(CFEs) during atrial fibrillation (AF) identified by an automated mapping algorithm: acute 
effects on AF and efficacy as an adjuvant strategy. Heart Rhythm. 2008;5:198-205. 
73. Verma A, Jiang CY, Betts TR, et al. Approaches to catheter ablation for 
persistent atrial fibrillation. N Engl J Med. 2015;372:1812-22. 
74. Sanders P, Berenfeld O, Hocini M, et al. Spectral analysis identifies sites of high-
frequency activity maintaining atrial fibrillation in humans. Circulation. 2005;112:789-97. 
75. Atienza F, Almendral J, Ormaetxe JM, et al. Comparison of radiofrequency 
catheter ablation of drivers and circumferential pulmonary vein isolation in atrial 
fibrillation: a noninferiority randomized multicenter RADAR-AF trial. J Am Coll Cardiol. 
2014;64:2455-67. 
76. Patterson E, Po SS, Scherlag BJ and Lazzara R. Triggered firing in pulmonary 
veins initiated by in vitro autonomic nerve stimulation. Heart Rhythm. 2005;2:624-31. 
77. Chen PS, Chen LS, Fishbein MC, Lin SF and Nattel S. Role of the autonomic 
nervous system in atrial fibrillation: pathophysiology and therapy. Circ Res. 
2014;114:1500-15. 
78. Katritsis DG, Pokushalov E, Romanov A, Giazitzoglou E, Siontis GC, Po SS, 
Camm AJ and Ioannidis JP. Autonomic denervation added to pulmonary vein isolation 
for paroxysmal atrial fibrillation: a randomized clinical trial. J Am Coll Cardiol. 
2013;62:2318-25. 
79. Narayan SM, Krummen DE, Shivkumar K, Clopton P, Rappel WJ and Miller JM. 
Treatment of atrial fibrillation by the ablation of localized sources: CONFIRM 
(Conventional Ablation for Atrial Fibrillation With or Without Focal Impulse and Rotor 
Modulation) trial. J Am Coll Cardiol. 2012;60:628-36. 
80. Narayan SM, Krummen DE, Donsky A, Swarup V and Miller JM. Precise Rotor 
Elimination without Concomitant pulmonary vein Isolation for the Successful Elimination 
of Paroxysmal ATrial Fibrillation. PRECISE-PAF. Heart rhythm 2013;10:LBCT4. 
 38 
81. Berntsen RF, Haland TF, Skardal R and Holm T. Focal impulse and rotor 
modulation as a stand-alone procedure for the treatment of paroxysmal atrial fibrillation: 
A within-patient controlled study with implanted cardiac monitoring. Heart Rhythm. 2016. 
82. Benharash P, Buch E, Frank P, Share M, Tung R, Shivkumar K and Mandapati 
R. Quantitative analysis of localized sources identified by focal impulse and rotor 
modulation mapping in atrial fibrillation. Circ Arrhythm Electrophysiol. 2015;8:554-61. 
83. Marrouche NF, Brachmann J and Committee CASTLE-AF. Catheter ablation 
versus standard conventional treatment in patients with left ventricular dysfunction and 
atrial fibrillation (CASTLE-AF) - study design. Pacing Clin Electrophysiol. 2009;32:987-
94. 
84. Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J, Kim YH, Klein 
G, Packer D and Skanes A. Worldwide survey on the methods, efficacy, and safety of 
catheter ablation for human atrial fibrillation. Circulation. 2005;111:1100-5. 
85. Sairaku A, Nakano Y, Oda N, Makita Y, Kajihara K, Tokuyama T and Kihara Y. 
Learning curve for ablation of atrial fibrillation in medium-volume centers. J Cardiol. 
2011;57:263-8. 
86. Sairaku A, Yoshida Y, Nakano Y, Maeda M, Hirayama H, Hashimoto H and 
Kihara Y. Who is the operator, that is the question: a multicentre study of catheter 
ablation of atrial fibrillation. Europace. 2016. 
87. Calkins H, Kuck KH, Cappato R, et al. 2012 HRS/EHRA/ECAS expert consensus 
statement on catheter and surgical ablation of atrial fibrillation: recommendations for 
patient selection, procedural techniques, patient management and follow-up, definitions, 
endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task 
Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership 
with the European Heart Rhythm Association (EHRA), a registered branch of the 
European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society 
(ECAS); and in collaboration with the American College of Cardiology (ACC), American 
Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the 
Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American 
College of Cardiology Foundation, the American Heart Association, the European 
Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of 
Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm 
Society. Heart Rhythm. 2012;9:632-696 e21. 
88. Jones DG, Haldar SK, Hussain W, Sharma R, Francis DP, Rahman-Haley SL, 
McDonagh TA, Underwood SR, Markides V and Wong T. A randomized trial to assess 
catheter ablation versus rate control in the management of persistent atrial fibrillation in 
heart failure. J Am Coll Cardiol. 2013;61:1894-903. 
89. Wokhlu A, Monahan KH, Hodge DO, Asirvatham SJ, Friedman PA, Munger TM, 
Bradley DJ, Bluhm CM, Haroldson JM and Packer DL. Long-term quality of life after 
ablation of atrial fibrillation the impact of recurrence, symptom relief, and placebo effect. 
J Am Coll Cardiol. 2010;55:2308-16. 
 39 
90. Khan MN, Jais P, Cummings J, et al. Pulmonary-vein isolation for atrial fibrillation 
in patients with heart failure. N Engl J Med. 2008;359:1778-85. 
91. Hunter RJ, Berriman TJ, Diab I, et al. A randomized controlled trial of catheter 
ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial). 
Circ Arrhythm Electrophysiol. 2014;7:31-8. 
92. MacDonald MR, Connelly DT, Hawkins NM, Steedman T, Payne J, Shaw M, 
Denvir M, Bhagra S, Small S, Martin W, McMurray JJ and Petrie MC. Radiofrequency 
ablation for persistent atrial fibrillation in patients with advanced heart failure and severe 
left ventricular systolic dysfunction: a randomised controlled trial. Heart. 2011;97:740-7. 
93. Di Biase L, Mohanty P, Mohanty S, et al. Ablation Versus Amiodarone for 
Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and 
an Implanted Device: Results From the AATAC Multicenter Randomized Trial. 
Circulation. 2016;133:1637-44. 
94. Van Gelder IC, Groenveld HF, Crijns HJ, et al. Lenient versus strict rate control in 
patients with atrial fibrillation. N Engl J Med. 2010;362:1363-73. 
95. Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, Kus T, Lambert 
J, Dubuc M, Gagne P, Nattel S and Thibault B. Amiodarone to prevent recurrence of 
atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med. 
2000;342:913-20. 
96. Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, 
Connolly SJ and Investigators. Effect of dronedarone on cardiovascular events in atrial 
fibrillation. N Engl J Med. 2009;360:668-78. 
97. Kober L, Torp-Pedersen C, McMurray JJ, Gotzsche O, Levy S, Crijns H, Amlie J, 
Carlsen J and Dronedarone Study Group. Increased mortality after dronedarone therapy 
for severe heart failure. N Engl J Med. 2008;358:2678-87. 
98. Connolly SJ, Camm AJ, Halperin JL, et al. Dronedarone in high-risk permanent 
atrial fibrillation. N Engl J Med. 2011;365:2268-76. 
99. Roy D, Pratt CM, Torp-Pedersen C, et al. Vernakalant hydrochloride for rapid 
conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. 
Circulation. 2008;117:1518-25. 
100. Pratt CM, Roy D, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, Retyk E, 
Drenning DH and Atrial Arrhythmia Conversion Trial Investigators. Usefulness of 
vernakalant hydrochloride injection for rapid conversion of atrial fibrillation. Am J Cardiol. 
2010;106:1277-83. 
101. Kowey PR, Dorian P, Mitchell LB, Pratt CM, Roy D, Schwartz PJ, Sadowski J, 
Sobczyk D, Bochenek A, Toft E and Atrial Arrhythmia Conversion Trial Investigators. 
Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac 
surgery: a randomized, double-blind, placebo-controlled trial. Circ Arrhythm 
Electrophysiol. 2009;2:652-9. 
 40 
102. Camm AJ, Capucci A, Hohnloser SH, Torp-Pedersen C, Van Gelder IC, Mangal 
B, Beatch G and Investigators. A randomized active-controlled study comparing the 
efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am 
Coll Cardiol. 2011;57:313-21. 
103. Jackson N, Atar D, Borentain M, et al. Improving clinical trials for cardiovascular 
diseases: a position paper from the Cardiovascular Round Table of the European 
Society of Cardiology. Eur Heart J. 2016;37:747-54. 
104. Boersma LV, Castella M, van Boven W, Berruezo A, Yilmaz A, Nadal M, 
Sandoval E, Calvo N, Brugada J, Kelder J, Wijffels M and Mont L. Atrial fibrillation 
catheter ablation versus surgical ablation treatment (FAST): a 2-center randomized 
clinical trial. Circulation. 2012;125:23-30. 
105. Pison L, La Meir M, van Opstal J, Blaauw Y, Maessen J and Crijns HJ. Hybrid 
thoracoscopic surgical and transvenous catheter ablation of atrial fibrillation. J Am Coll 
Cardiol. 2012;60:54-61. 
106. Muneretto C, Bisleri G, Bontempi L and Curnis A. Durable staged hybrid ablation 
with thoracoscopic and percutaneous approach for treatment of long-standing atrial 
fibrillation: a 30-month assessment with continuous monitoring. J Thorac Cardiovasc 
Surg. 2012;144:1460-5; discussion 1465. 
107. Kirchhof P, Breithardt G, Aliot E, et al. Personalized management of atrial 
fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European 
Heart Rhythm Association consensus conference. Europace. 2013;15:1540-56. 
108. Goette A, Kalman JM, Aguinaga L, et al. EHRA/HRS/APHRS/SOLAECE expert 
consensus on Atrial cardiomyopathies: definition, characterization, and clinical 
implication. Europace. 2016. 
109. Oakes RS, Badger TJ, Kholmovski EG, et al. Detection and quantification of left 
atrial structural remodeling with delayed-enhancement magnetic resonance imaging in 
patients with atrial fibrillation. Circulation. 2009;119:1758-67. 
110. Marrouche NF, Wilber D, Hindricks G, et al. Association of atrial tissue fibrosis 
identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the 
DECAAF study. JAMA. 2014;311:498-506. 
111. Peters DC, Wylie JV, Hauser TH, Kissinger KV, Botnar RM, Essebag V, 
Josephson ME and Manning WJ. Detection of pulmonary vein and left atrial scar after 
catheter ablation with three-dimensional navigator-gated delayed enhancement MR 
imaging: initial experience. Radiology. 2007;243:690-5. 
112. Badger TJ, Daccarett M, Akoum NW, et al. Evaluation of left atrial lesions after 
initial and repeat atrial fibrillation ablation: lessons learned from delayed-enhancement 
MRI in repeat ablation procedures. Circ Arrhythm Electrophysiol. 2010;3:249-59. 
113. Chen YH, Xu SJ, Bendahhou S, et al. KCNQ1 gain-of-function mutation in 
familial atrial fibrillation. Science. 2003;299:251-4. 
 41 
114. Olson TM, Alekseev AE, Liu XK, Park S, Zingman LV, Bienengraeber M, 
Sattiraju S, Ballew JD, Jahangir A and Terzic A. Kv1.5 channelopathy due to KCNA5 
loss-of-function mutation causes human atrial fibrillation. Hum Mol Genet. 2006;15:2185-
91. 
115. Darbar D, Kannankeril PJ, Donahue BS, Kucera G, Stubblefield T, Haines JL, 
George AL, Jr. and Roden DM. Cardiac sodium channel (SCN5A) variants associated 
with atrial fibrillation. Circulation. 2008;117:1927-35. 
116. Gollob MH, Jones DL, Krahn AD, et al. Somatic mutations in the connexin 40 
gene (GJA5) in atrial fibrillation. N Engl J Med. 2006;354:2677-88. 
117. Hodgson-Zingman DM, Karst ML, Zingman LV, Heublein DM, Darbar D, Herron 
KJ, Ballew JD, de Andrade M, Burnett JC, Jr. and Olson TM. Atrial natriuretic peptide 
frameshift mutation in familial atrial fibrillation. N Engl J Med. 2008;359:158-65. 
118. Zhang X, Chen S, Yoo S, et al. Mutation in nuclear pore component NUP155 
leads to atrial fibrillation and early sudden cardiac death. Cell. 2008;135:1017-27. 
119. Ellinor PT, Lunetta KL, Albert CM, et al. Meta-analysis identifies six new 
susceptibility loci for atrial fibrillation. Nat Genet. 2012;44:670-5. 
120. Darbar D and Roden DM. Genetic mechanisms of atrial fibrillation: impact on 
response to treatment. Nat Rev Cardiol. 2013;10:317-29. 
121. Otway R, Vandenberg JI, Guo G, et al. Stretch-sensitive KCNQ1 mutation A link 
between genetic and environmental factors in the pathogenesis of atrial fibrillation? J Am 
Coll Cardiol. 2007;49:578-86. 
122. Parvez B, Vaglio J, Rowan S, Muhammad R, Kucera G, Stubblefield T, Carter S, 
Roden D and Darbar D. Symptomatic response to antiarrhythmic drug therapy is 
modulated by a common single nucleotide polymorphism in atrial fibrillation. J Am Coll 
Cardiol. 2012;60:539-45. 
123. Parvez B, Shoemaker MB, Muhammad R, Richardson R, Jiang L, Blair MA, 
Roden DM and Darbar D. Common genetic polymorphism at 4q25 locus predicts atrial 
fibrillation recurrence after successful cardioversion. Heart Rhythm. 2013;10:849-55. 
124. Shoemaker MB, Bollmann A, Lubitz SA, et al. Common genetic variants and 
response to atrial fibrillation ablation. Circ Arrhythm Electrophysiol. 2015;8:296-302. 
125. Choi EK, Park JH, Lee JY, Nam CM, Hwang MK, Uhm JS, Joung B, Ko YG, Lee 
MH, Lubitz SA, Ellinor PT and Pak HN. Korean Atrial Fibrillation (AF) Network: Genetic 
Variants for AF Do Not Predict Ablation Success. J Am Heart Assoc. 2015;4:e002046. 
126. Parvez B, Chopra N, Rowan S, Vaglio JC, Muhammad R, Roden DM and Darbar 
D. A common beta1-adrenergic receptor polymorphism predicts favorable response to 
rate-control therapy in atrial fibrillation. J Am Coll Cardiol. 2012;59:49-56. 
 42 
127. Mohanty S, Hall AW, Mohanty P, et al. Novel association of polymorphic genetic 
variants with predictors of outcome of catheter ablation in atrial fibrillation: new directions 
from a prospective study (DECAF). J Interv Card Electrophysiol. 2015. 
128. Lubitz SA, Yin X, Lin H, et al. Genetic Risk Prediction of Atrial Fibrillation. 
Circulation. 2016. 
129. Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus 
statement on the state of genetic testing for the channelopathies and cardiomyopathies 
this document was developed as a partnership between the Heart Rhythm Society 
(HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm. 
2011;8:1308-39. 
130. Biankin AV, Piantadosi S and Hollingsworth SJ. Patient-centric trials for 
therapeutic development in precision oncology. Nature. 2015;526:361-70. 
131. Hess CN, Rao SV, Kong DF, et al. Embedding a randomized clinical trial into an 
ongoing registry infrastructure: unique opportunities for efficiency in design of the Study 
of Access site For Enhancement of Percutaneous Coronary Intervention for Women 
(SAFE-PCI for Women). Am Heart J. 2013;166:421-8. 
132. Committee for Medicinal Products for Human Use (CHMP); European Medicines 
Agency. Reflection paper on methodological issues in confirmatory clinical trials planned 
with an adaptive design. 2007. 
133. Boriani G, Glotzer TV, Santini M, West TM, De Melis M, Sepsi M, Gasparini M, 
Lewalter T, Camm JA and Singer DE. Device-detected atrial fibrillation and risk for 
stroke: an analysis of >10,000 patients from the SOS AF project (Stroke preventiOn 
Strategies based on Atrial Fibrillation information from implanted devices). Eur Heart J. 
2014;35:508-16. 
134. Odutayo A, Wong CX, Hsiao AJ, Hopewell S, Altman DG and Emdin CA. Atrial 
fibrillation and risks of cardiovascular disease, renal disease, and death: systematic 
review and meta-analysis. BMJ. 2016;354:i4482. 
135. Wazni OM, Marrouche NF, Martin DO, et al. Radiofrequency ablation vs 
antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized 
trial. JAMA. 2005;293:2634-40. 
136. Pappone C, Augello G, Sala S, et al. A randomized trial of circumferential 
pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial 
fibrillation: the APAF Study. J Am Coll Cardiol. 2006;48:2340-7. 
137. Kuck KH, Brugada J, Furnkranz A, et al. Cryoballoon or Radiofrequency Ablation 
for Paroxysmal Atrial Fibrillation. N Engl J Med. 2016;374:2235-45. 
138. Verma A, Mantovan R, Macle L, De Martino G, Chen J, Morillo CA, Novak P, 
Calzolari V, Guerra PG, Nair G, Torrecilla EG and Khaykin Y. Substrate and Trigger 
Ablation for Reduction of Atrial Fibrillation (STAR AF): a randomized, multicentre, 
international trial. Eur Heart J. 2010;31:1344-56. 
  
 43 
Figure legends 
 
Figure 1. Atrial fibrillation ablation strategies. Schematic posterior view of the left and 
right atria with example ablation lesion sets. A. Pulmonary vein isolation with 
circumferential ablation lesions and B. Linear lesion sets including: a) roof line, b) mitral 
isthmus line, c) anterior linear lesion, d) cavotricuspid isthmus line, e) additional linear 
lesions between the superior and inferior pulmonary veins, f) electrical isolation of the 
superior vena cava. C. Common sites of ablation when complex fractionated 
electrograms are targeted. D. Sites of the major left atrial autonomic ganglionated plexi 
(GP) and axons (superior left GP, inferior left GP, anterior right GP, inferior right GP, and 
ligament of Marshall). IVC, inferior vena cava; LIPV, left inferior pulmonary vein; LSPV, 
left superior pulmonary vein; RIPV, right inferior pulmonary vein; RSPV, right superior 
pulmonary vein. Figure adapted from Calkins et al.87   
 
Figure 2. Proposed algorithm for personalised atrial fibrillation care. *Management/ 
clinical trial allocation’ adapted from Biankin et al.130 
Table 1. Clinical studies of lifestyle modification for atrial fibrillation prevention 
 
Study  Design Patient population N Intervention Comparator Endpoints Follow-up 
(mean±SD) 
Outcomes 
Abed et 
al.25 
RCT 
Single-blind 
Single-centre 
Obese (BMI>27kg/m2). 
PAF (58%) or persistent AF 
Mean age 60±10y 
67% male 
150 Physician-
led weight 
loss and 
RFM 
programme 
Self-directed 
general 
lifestyle 
measures 
Primary: 
Symptom burden 
and severity 
Secondary: 
AF burden and 
echocardiographic 
parameters 
Control 
12.0±4.0 
months 
Intervention 
12.9±2.6 
months 
RFM resulted in greater weight 
loss (from mean BMI 32.8kg/m2 
to 27.2kg/m2) and improved 
cardiometabolic profile, reduced 
symptom burden and severity, 
decreased AF burden, LA area 
and LV wall thickness 
ARREST-
AF 
Pathak et 
al.26 
Prospective 
cohort  
Single-centre 
Obese (BMI≥27kg/m2). 
≥1 cardiometabolic risk factor 
Initial catheter ablation  
Symptomatic PAF (60%) or 
persistent AF despite anti-
arrhythmic therapy 
Pooled mean age 58±10y 
64% male 
149 Physician-
led weight 
loss and 
RFM 
programme 
Self-directed 
general 
lifestyle 
measures  
Primary: 
Recurrent AF 
Secondary: 
AF frequency, 
duration, and 
symptom burden 
Control 
42.1±14.2 
months  
Intervention4
1.6±12.5 
months 
 
RFM resulted in greater weight 
loss and improved 
cardiometabolic profile, greater 
freedom from AF after a single or 
multiple ablation procedures, 
and greater reduction in AF 
frequency, duration, symptoms 
and symptom severity.   
LEGACY 
Pathak et 
al.27 
Prospective 
cohort 
Single-centre 
Obese (BMI≥27kg/m2). 
PAF (53%) and persistent AF 
Weight loss categorized as: ≥10% 
(group 1), 3-9% (group 2), <3% 
(group 3) 
Pooled mean age 63±11y 
66% male 
825 Physician-
led weight 
loss and 
RFM 
programme 
 
n/a 
Primary: 
AF burden 
Secondary: 
Echocardiographic 
parameters 
34±15 
months 
Greatest improvement in AF 
burden and symptom severity in 
group 1. 
Greatest benefit in patients with 
stable (vs. fluctuating) weight 
after initial weight loss. 
Groups 1 and 2 had reductions 
in LA area and LV wall 
thickness.  
CARDIO-
FIT 
Pathak et 
al.31 
 
Prospective 
cohort 
Obese (BMI≥27kg/m2) and able to 
undergo exercise training. 
Symptomatic PAF (53%) or 
persistent AF 
Baseline CRF categorized as low 
(<85% predicted METs), 
adequate (86-100% predicted 
METs), high (>100% predicted 
METs) 
Improvement in CRF categorized 
as ≥2METs vs. <2METs 
Pooled mean age 60±11y 
48%male 
308 Physician-
led weight 
loss, RFM, 
and tailored 
exercise 
programme 
 
n/a 
Primary: 
Freedom from AF 
and symptom 
burden 
Secondary: 
echocardiographic 
parameters 
49±19 
months 
Greatest ablation and drug-free 
AF-free survival and reduction in 
symptoms in patients with high 
CRF (vs. low or adequate CRF). 
Greater reduction in AF burden 
and symptom severity in patients 
with ≥2METs gain in CRF (vs. 
<2METs). 
More favourable reductions in LA 
area and LV wall thickness in 
patients with ≥2METs gain in 
CRF (vs. <2METs). 
Malmo et 
al.32 
RCT 
Single-blind 
Single-centre 
Paroxysmal (57%) or persistent 
AF, able to undergo exercise 
training. 
Pooled mean age 59±8y 
82% male 
51 Aerobic 
interval 
training 
Self-directed 
usual 
exercise 
regimen 
Primary: 
AF burden 
Secondary: 
VO2, 
echocardiographic 
parameters, lipid 
status, quality of 
life, AF-related 
hospital admissions. 
4 weeks Aerobic interval training was 
associated with reduced AF 
burden, improvement in AF 
symptoms, peak VO2, quality of 
life, and LA and LV function. 
 
CRF, cardiorespiratory fitness; LA, left atrium; LV, left ventricular; METs, metabolic equivalents; PAF, paroxysmal AF; RCT, 
randomised controlled trial; RFM, risk factor management; VO2; oxygen uptake. 
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Table 2. Randomised clinical trials of catheter ablation for atrial fibrillation 
 
Study  Design Patient population N Intervention Comparator Endpoints Follow-up 
(mean±SD) 
Outcomes 
1st line therapy 
RAAFT-1 
Wazni et 
al.135 
RCT 
Multicentre 
Symptomatic PAF (96%) 
and persistent AF 
Pooled mean age 53±8y 
% male not reported 
 
70 PVI AAD Primary: 
Recurrent AF  
Secondary: 
Hospitalisation, 
quality of life 
12 months 87% PVI vs. 37% AAD group freedom from AF 
recurrence 
9% PVI vs 54% AAD hospitalisation 
Greater improvement in quality of life with PVI 
MANTRA-
PAF 
Cosedis 
Nielson et 
al.54 
RCT 
Multicentre 
Symptomatic PAF 
Pooled mean age 55±10y 
70% male 
294 PVI+ 
additional 
ablation at 
operator’s 
discretion 
AAD Primary: 
Burden of AF 
Secondary: 
Freedom from 
AF, symptoms, 
time to first 
recurrence, 
quality of life 
24 months No significant difference in cumulative burden 
of AF 
9% PVI vs 18% AAD AF burden at 24 months 
85% PVI vs. 71% AAD freedom from any AF 
recurrence 
Quality of life improved equally in both groups. 
RAAFT-2 
Morillo et 
al.52 
RCT 
Multicentre 
Symptomatic PAF 
Pooled mean age 55±10y 
76% male 
127 PVI + 
additional 
ablation at 
operator’s 
discretion 
AAD Primary: 
Recurrent AF 
Secondary: 
Symptomatic 
AF, quality of life 
24 months 45% PVI vs. 28% AAD freedom from AF 
recurrence 
53% PVI vs 41% AAD freedom from recurrent 
symptomatic AF 
Quality of life improved equally in both groups 
2nd line therapy 
A4 Study 
Jais et al.51 
RCT 
Multicentre 
Superiority 
Symptomatic drug-
refractory PAF 
Pooled mean age 51±11y 
84% male 
108 PVI+ 
additional 
ablation at 
operator’s 
discretion 
AAD Primary: 
Recurrent AF at 
3-12 months, 
freedom from 
AF after 
≤3procedures, 
12 months Greater freedom from AF in the ablation (89%) 
vs AAD (23%) group. 
More favourable symptom scores, exercise 
capacity, and quality of life in the ablation 
group. 
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changes in AAD 
within 3 months 
Secondary: 
Time to 
recurrent AF, 
quality of life, 
exercise 
capacity, AF 
burden 
APAF 
study 
Pappone 
et al.136 
RCT 
Single-
centre 
Symptomatic drug-
refractory PAF 
Pooled mean age 56±10y 
67% male 
198 PVI+ 
additional 
ablation at 
operator’s 
discretion 
AAD Primary: 
Freedom from 
AF at 12 months 
 
12 months Greater freedom from AF in the ablation vs. 
AAD group (93% vs. 35% at 1 year). 
Fewer cardiovascular hospitalisations in 
ablation group.  
Wilber et 
al.55 
RCT 
Multicentre 
Symptomatic drug-
refractory PAF 
Pooled mean age 56y 
(95%CI 54.1-57.4) 
67% male 
 
167 PVI+ 
additional 
ablation at 
operator’s 
discretion 
AAD Primary: 
Freedom from 
symptomatic AF; 
safety 
Secondary: 
Freedom from 
any atrial 
arrhythmia, 
quality of life 
 
PVI group: 
median 12.5 
(95%CI 
11.9-13.1) 
months 
AAD group: 
median 
14.3(95%CI9
.4-15.5) 
months 
Greater freedom from AF in the ablation vs. 
AAD group (66% vs. 16% at 9 months). 
Greater freedom from any atrial arrhythmia in 
the ablation vs. AAD group (70% vs. 19% at 9 
months). 
More favourable quality of life scores in the 
ablation vs. AAD group. 
 
AAD, antiarrhythmic drug therapy; PVI, pulmonary vein isolation. 
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Table 3. Seminal clinical trials of novel techniques for atrial fibrillation ablation  
 
Study  Design Patient 
population 
N Intervention Comparator Endpoints Follow-up 
(mean±SD) 
Outcomes 
Contact force 
TOCCASTAR 
Reddy et al.59 
RCT 
Multicentre 
Non-
inferiority 
Symptomatic 
drug-refractory 
PAF  
Pooled mean age 
60±10y 
65% male 
 
295 Ablation with 
CF-sensing 
catheter 
Ablation with 
non-CF 
catheter 
Primary: Efficacy 
(acute PVI; freedom 
from symptomatic AF 
off AAD); safety 
Secondary: 
Optimal vs. non-
optimal CF; quality of 
life 
12 months Efficacy: 67.8% CF vs. 69.4% control (non-
inferiority endpoint met) 
Efficacy within stratified CF arm: 75.9% 
optimal CF, vs. 58.1% non-optimal CF 
Serious adverse events in 2.0% CF vs. 1.4% 
control (safety non-inferior end point met) 
Cryoablation 
FIRE and ICE 
Kuck et al.137 
RCT 
Multicentre 
Non-
inferiority 
Symptomatic 
drug-refractory 
PAF  
Pooled mean age 
60±10y 
61% male 
750 Cryoablation Standard 
ablation 
Primary: Efficacy 
(time to first 
recurrence of 
arrhythmia, AAD use 
or repeat ablation); 
safety 
Secondary: 
Quality of life 
18 months Non-inferiority efficacy and safety endpoints 
met 
No significant difference among the four 
types of ablation catheters. 
CFAE 
STAR AF 
Verma et 
al.138 
RCT 
Multicentre 
Superiority 
Symptomatic 
drug-refractory 
PAF (65%) or 
persistent AF 
Pooled mean age 
57±10y 
74% male 
100 1. CFE alone 
2. CFE+PVI 
PVI alone Primary: Freedom 
from AF 
Secondary: 
Freedom from any 
arrhythmia, 
complications, 
procedural 
characteristics 
12 months PVI+CFE had the highest freedom from AF 
vs PVI alone or CFE alone. 
CFE alone had the lowest success rate after 
one- or two-procedures, and a higher 
incidence of repeat procedures required. 
STAR AF II RCT Symptomatic 589 1. PVI + PVI alone Primary: Freedom 18 months No significant difference in outcomes 
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Verma et al.73 Multicentre drug-refractory 
persistent AF 
Pooled mean age 
60±9y 
78% male 
CFAE 
2. PVI + 
linear 
ablation 
from atrial arrhythmia 
after index ablation 
off AAD or repeat 
ablation 
Secondary: 
Freedom from any AF 
after 2 procedures, 
freedom from any 
atrial arrhythmia, AAD 
use, complications, 
procedural 
characteristics 
between groups after a first or repeat 
procedure. 
PVI alone tended to be associated with 
shorter procedure and radiation times. 
Rotor modulation 
CONFIRM 
Narayan et 
al.79 
RCT 
Single-
centre 
Symptomatic PAF 
(28%) or 
persistent AF 
Pooled mean age 
62±8y 
95% male 
92 FIRM-guided 
ablation 
+conventiona
l ablation 
Conventional 
ablation: 
WACA (+LA 
roof line for 
persistent 
AF cases) 
Primary: Acute 
procedural 
termination of AF, 
long-term freedom 
from AF, safety 
Secondary: 
Freedom from AF 
following first 
ablation, freedom 
from all atrial 
arrhythmias 
Median 22 
months 
Acute procedural endpoint achieved in 86% 
FIRM-guided vs. 20% conventional ablation 
cases 
Total ablation time the same for both groups 
Greater freedom from AF for FIRM-guided 
(82%) vs. conventional (45%) after a single 
procedure 
Safety: no significant difference in 
complication rates between groups.  
Dominant frequency ablation 
RADAR AF 
Atienza et 
al.75 
RCT 
Multicentre 
Single-blind 
Non-
inferiority 
Symptomatic PAF 
(50%) and 
persistent AF 
Pooled mean age 
54±10y 
80% male 
232 PAF: HFSA 
Persistent 
AF: PVI 
PAF: PVI 
Persistent 
AF: 
PVI+HFSA 
Primary: Freedom 
from AF at 6 months 
post index ablation 
Secondary: 
Freedom from AF/AT 
at 6 and 12 months; 
periprocedural 
complications; 
adverse events; 
quality of life. 
12 months PAF: HFSA was non-inferior to PVI at 12 
months (failed to achieve non-inferiority at 6 
months). Fewer serious adverse events in 
the HFSA group. 
Persistent AF: No significant difference 
between HFSA and PVI for primary or 
secondary endpoints, but a trend towards 
more serious adverse events with 
PVI+HFSA. 
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Adenosine 
ADVICE 
Macle et al.61 
RCT 
Multicentre 
Superiority 
 
Symptomatic AF 
undergoing 
ablation 
Pooled mean 
age 60±10y 
71% male 
534 PVI + 
adenosine 
guided 
dormant 
conduction 
ablation 
PVI alone Primary: Time to first 
recurrence of atrial 
tachyarrhythmia after 
index ablation or 
repeat ablation <1 
year 
Secondary: 
Time to first 
recurrence of atrial 
tachyarrhythmia; AAD 
use; periprocedural 
complications 
12.2±1.4 
months 
Adenosine unmasked dormant PV 
conduction in 53% of patients. 
Adenosine guided ablation associated with 
greater freedom from AF (69% vs. 42%).  
Similar occurrence of serious adverse events 
in each group.  
UNDER-ATP 
Kobori et al.62 
RCT 
Multicentre 
Superiority 
 
Symptomatic 
PAF or persistent 
AF undergoing 
first-time ablation 
Pooled mean 
age 63.3±10y 
74% male 
2113 PVI + 
adenosine 
guided 
dormant 
conduction 
ablation 
PVI alone Primary: Recurrent 
atrial tachyarrhythmia 
<1 year 
Secondary: Repeat 
ablation for any atrial 
tachyarrhythmia; 
periprocedural 
complications 
Median 384 
days 
(interquartile 
range 366-
450 days) 
No significant difference in the incidence of 
recurrent atrial tachyarrhythmias at 1 year 
between the 2 groups. 
Ganglion plexi ablation 
Katritsis et al. 
78 
RCT 
2 centre 
 
Symptomatic PAF 
Pooled mean age 
56±8y 
66% male 
242 1. PVI + 
ganglion 
plexi 
ablation 
2. Ganglion 
plexi 
ablation 
alone 
PVI alone Primary: Freedom 
from AF/AT after 
index ablation 
Secondary: 
RF delivery time, 
fluoroscopy time, 
adverse events 
2 years Addition of GP ablation to PVI conferred a 
significantly higher success rate compared 
with either PVI or GP alone in patients with 
PAF. 
AAD, antiarrhythmic drug; AT, atrial tachycardia; CF, contact force; CFAE, contact force atrial electrograms; FIRM, focal impulse and 
rotor modulation; HFSA, high frequency source ablation; PVI, pulmonary vein isolation; WACA, wide area circumferential ablation. 
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Table 4. Randomised controlled trials of atrial fibrillation ablation in patients with heart failure 
 
Study  Design Patient population N Intervention Comparator Endpoints Follow-up Outcomes 
PABA-
CHF 
Khan et 
al.90 
RCT 
Multicentr
e 
Symptomatic HF (EF≤40%) 
and PAF (49%) or persistent 
AF. 
LVEF 27-35% 
NYHA class 2-3 
Pooled mean age 60±8y 
91% male 
81 PVI + 
additional 
ablation at 
operator’s 
discretion 
AV node 
ablation with 
biventricular 
pacing 
Primary: Composite of 
improvement in EF, 
6MWD, QOL score vs. 
baseline 
Secondary: Freedom 
from AF, LA 
dimensions 
6 months Significance criteria for the primary 
composite endpoint met. 
Improved QOL and 6MWD in the 
ablation group. 
MacDonal
d et al.92 
RCT 
Multicentr
e 
Symptomatic HFrEF 
(EF<35%), persistent AF 
LVEF 36-41% 
NYHA class 2-4, mean 2.9 
Pooled mean age 63±7y 
78% male 
41 PVI + linear 
ablation + 
CFAE 
ablation 
+medical 
therapy 
Medical 
therapy: HF 
therapy 
(+digoxin if 
HR>80bpm) 
Primary: EF by CMR 
Secondary: EF by 
radionuclide imaging, 
6MWD, NT-proBNP, 
quality of life, other 
CMR indices 
6 months No significant difference in EF 
improvement between the groups 
No difference in QOL and 6MWD 
between groups. 
ARC-HF 
Jones et 
al.88 
 
RCT 
Single 
centre 
Symptomatic HFrEF 
(EF≤35%) and persistent AF 
LVEF 21-32% 
NYHA class 2-4, mean 2.4 
Pooled mean age 63±9y 
87% male 
52 PVI+ linear 
ablation 
+CFAE 
ablation 
Rate control Primary: Change in 
peak VO2 at 12 
months 
Secondary: Quality of 
life, BNP, 6MWD, EF 
12 months Improved QOL and peak VO2 
(+3ml/kg/min difference) and reduced 
BNP in the ablation group. 
Non-significant improvements in 6MWD 
and EF 
CAMTAF 
Hunter et 
al.91 
RCT 
Single 
centre 
Symptomatic HFrEF 
(EF<50%) and persistent AF 
LVEF 32-40% 
NYHA class 2-4, mean 2.7 
Pooled mean age 57±11y 
87% male 
50 PVI+ 
additional 
ablation at 
operator’s 
discretion 
Rate control Primary: 
EF at 6 months,  
Secondary: 
% reduction in LVESV 
at 6 months, peak 
VO2, BNP, NYHA 
class, quality of life 
6 months Improved QOL, NYHA class, peak VO2 
and reduced BNP in the ablation group. 
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AATAC 
Di Biase 
et al.93 
RCT 
Multicentr
e 
HFrEF (EF≤40%), persistent 
AF, and an implanted device 
(CRTD/ICD) 
LVEF 29±5% 
NYHA class 2-3 
Pooled mean age 61±10y 
74% male 
203 PVI+ 
additional 
ablation at 
operator’s 
discretion 
Amiodarone Primary: 
Freedom from AF,  
Secondary: 
All-cause mortality, 
unplanned AF- and 
HF-related hospital 
admissions, change in 
LVEF, 6MWD, quality 
of life 
2 years Greater freedom from AF in the ablation 
group (70%) vs amiodarone group 
(34%) after 2 years. 
Improved QOL, exercise capacity, 
reduced unplanned hospital admissions 
and reduced mortality in the ablation 
group. 
Trials in progress 
CASTLE 
AF 
Marrouche 
et al.83  
RCT 
Multicentre 
Symptomatic HFrEF and 
AF 
https://clinicaltrials.gov/ct2/
show/NCT00643188 
 
420 PVI+ 
additional 
ablation at 
operator’s 
discretion 
Conventiona
l therapy 
Primary: All-cause 
mortality or worsening 
HF requiring 
unplanned 
hospitalisation 
Minimum 3 
years 
 
RAFT AF 
Tang, 
Wells et 
al. 
RCT 
Multicentre 
Symptomatic HFrEF or 
HFpEF (NYHA class 2-3) 
PAF or persistent or long-
term persistent AF 
https://clinicaltrials.gov/ct2/
show/NCT01420393 
 
 
 PVI+ 
additional 
ablation at 
operator’s 
discretion 
Rate control Primary: Composite 
of all-cause mortality 
and hospitalization for 
heart failure 
5 years  
EAST 
Kirchhof et 
al. 
RCT 
Multicentre 
Symptomatic PAF or 
persistent AF. 
Includes patients with 
HFrEF (EF<50%) 
https://clinicaltrials.gov/ct2/
show/NCT01288352 
 
 Early rhythm 
control: 
1. AAD 
2. PVI 
3. Combined 
AAD + 
PVI 
Usual care: 
rate control 
as 1st line; 
rhythm 
control for 
patients with 
refractory 
symptoms 
Primary: A 
composite of 
cardiovascular death, 
stroke, or 
hospitalization due to 
worsening of heart 
failure or acute 
coronary syndrome 
8 years  
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CABANA 
Packer et 
al. 
RCT 
Multicentre 
Symptomatic PAF, 
persistent or longstanding 
persistent AF. 
Includes patients with 
HFrEF and HFpEF 
https://clinicaltrials.gov/ct2/
show/NCT00911508 
 PVI + 
additional 
ablation at 
operator’s 
discretion 
AAD or rate 
control 
Primary: A 
composite of total 
mortality, disabling 
stroke, serious 
bleeding or cardiac 
arrest 
  
 
BNP, brain natriuretic peptide; EF, ejection fraction; LVESV, left ventricular end systolic volume; NYHA, New York Heart Association 
class; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; VO2, peak exercise 
oxygen consumption. 
